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ABSTRACT 
For decades, warfarin was the only oral anticoagulant available for the prevention of stroke and 
systemic embolism in atrial fibrillation. Since 2010, four non-vitamin K antagonist oral 
anticoagulant agents have gained the Food and Drug Administration approval for this indication: 
dabigatran, rivaroxaban, apixaban and edoxaban.  
Chapter 1 provides an introduction to the three research manuscripts that constitute this 
dissertation. It reviews the use of anticoagulation therapy in atrial fibrillation and especially the 
evidence on non-vitamin K antagonist oral anticoagulants.  
Chapter 2 (Manuscript 1) is a retrospective cohort study that compares the risk of stroke and 
bleeding with rivaroxaban 20mg/dabigatran 150mg, and rivaroxaban 15mg/dabigatran 75mg. 
This study found no difference in the risk of stroke between dabigatran and rivaroxaban; 
however, rivaroxaban 20mg and rivaroxaban 15mg were associated with higher risk of 
thromboembolic events other than stroke, death, major bleeding, and any bleeding events than 
dabigatran 150mg and dabigatran 75mg. 
Chapter 3 (Manuscript 2) evaluates the patterns of anticoagulation use following a major 
bleeding on dabigatran or warfarin, and compares the thromboembolic and bleeding risk between 
post-hemorrhage treatment groups. In this study, post-hemorrhage resumption of anticoagulation 
with either dabigatran or warfarin was associated with increased survival and stroke-free 
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 v 
survival, as compared to discontinuing anticoagulation. In addition, this paper revealed that the 
risk of recurrent major hemorrhage was higher with warfarin than dabigatran. 
Chapter 4 (Manuscript 3) is a cost-effectiveness study that compares edoxaban 60mg, 
apixaban 5mg, dabigatran 150mg, dabigatran 110mg, rivaroxaban 20mg and dose-adjusted 
warfarin in the prevention of stroke in atrial fibrillation patients with high risk of bleeding, as 
defined by HAS-BLED score ≥3. This study found that, while apixaban 5mg was the most 
effective strategy, its incremental cost-effectiveness ratio when compared to edoxaban was 
slightly above the $100,000 per quality-adjusted life-year threshold.  
Public Health Significance 
The investigations reported in this dissertation will guide clinicians in the prescription of the 
most appropriate anticoagulation agent according to the clinical characteristics of atrial 
fibrillation patients. This will ultimately lead to the prevention of strokes, the second leading 
cause of mortality worldwide, and bleeding events, the most common complication of 
anticoagulation therapy.  
Key Words 
Anticoagulation; Atrial fibrillation; Hemorrhage; Non-vitamin K antagonist oral 
anticoagulants; Stroke; Warfarin. 
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PREFACE 
"They shall find wisdom here and faith, in steel and stone, in character and thought; they shall 
find beauty, adventure and moments of high victory". I came across this quote by Chancellor 
John Bowman in February 2013, when I received the letter of acceptance to this PhD program. 
Three years later, I have come to realize that, as Chancellor Bowman predicted, Pitt put in my 
path many treasures other than scientific training:  
Faith: in these three years I learned to believe, especially in myself, in science, and in the 
existence of a society that appreciates science. A wise society where research matters, influences 
opinions, impacts decisions and models common knowledge. My time in this program also 
sharpened my mind, instilling in me not only the analytical and critical traits of a scientific brain, 
but also the ability to become fascinated by research. Isn’t it beautiful to work on something that 
has the power to delight you? An ocean away from home, each day was full of an endless sense 
of adventure and enjoyment. Each day was also full of warmth, that one you feel when you are 
greatly welcomed in the heart of a continent that is not yours—I will dare to say though, that 
after these three years, America is starting to feel a bit like mine too. And what can I say about 
victory? I do not conceive moments of higher victory than going to school every morning to 
work on something you care about, with the support of an extraordinary group of people 
believing in what you do.  
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As I leave this PhD program, I feel extremely happy and honored to remain in the Pitt 
family for a few more years. I only hope that through my work, I can help new Pitt students in 
their own search of wisdom, faith, beauty, adventure and victory.  
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1.0  INTRODUCTION 
1.1 ATRIAL FIBRILLATION AND RISK OF STROKE 
1.1.1 Epidemiology of Atrial Fibrillation 
Atrial fibrillation (AF) is the most prevalent type of sustained cardiac arrhythmia, and it is 
characterized by a disorganized atrial electrical activity.1 It is estimated that between 2 and 3 
million people were affected by AF in the US in 2010, and over 30 million worldwide.2-4 Every 
year, there are approximately 200,000-400,000 new cases of AF in the US, and 5 million 
worldwide.2,5  
The prevalence of AF increases with age, ranging from 0.1% in patients younger than 55 
years to around 9% in those older than 90 years.3 In 2010, over 70% of US patients with AF 
were at least 65 years old, and 45% were older than 75.2 As the population ages, the prevalence 
of AF will increase: it has been estimated that by 2050, around 7.5-12 million Americans and 18 
million Europeans will be affected by AF.4,6  
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1.1.2 Thrombogenesis in Atrial Fibrillation 
In 1856, the German physician Virchow proposed three factors that contribute to thrombosis: 
abnormal blood stasis, structural abnormalities, and abnormal  blood constituents.7 All three 
factors in Virchow’s triad for thrombogenesis are present in AF.8  
1.1.2.1 Abnormal Stasis of Blood 
In AF, many impulses originate simultaneously and spread through the atria, competing with 
each other.1 The resulting atrial rhythm is disorganized, rapid and irregular, which results in an 
uncoordinated atrial contraction.9 The loss of coordinated contraction promotes the stagnation of 
blood in the left atrium and, especially, in the left atrial appendage.10 The left atrial appendage is 
a blind-ended passage with a narrow inlet and variable morphology that predisposes to blood 
stasis.  
1.1.2.2 Structural Abnormalities 
AF is associated with a progressive dilatation of the left atrium and the left atrial appendage, 
which amplifies the potential for blood stasis.11,12 In addition, the left atrial endocardium of AF 
patients presents morphological changes characterized  by a granular and wrinkled appearance.13 
This so called “rough endocardium” is associated with edema and fibrinous transformation, and 
presents numerous areas of endocardial denudation and thrombotic aggregation.10 Finally, the 
turnover of the atrial extracellular matrix is disrupted in AF, which is evidenced by the  altered 
amounts of products of collagen degradation observed in AF patients.14 This disrupted 
extracellular matrix has the potential of inducing fibrosis and infiltration of the endocardium, 
also promoting the thrombogenesis.10 
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1.1.2.3 Abnormal Blood Constituents 
AF patients present increased levels of plasma markers of thrombogenesis, including thrombin-
antithrombin complexes and fibrin D-dimers, as well as increased levels of platelet activation 
markers, such as beta-thromboglubin or platelet factor 4.15-18 These abnormalities in blood 
constituents, together with the increased levels of pro-angiogenic markers such as vascular 
endothelial growth factor (VEGF), angiopoietin-1, or angiopoietin-2, suggest the presence of a 
hypercoagulable state in AF.8,19-21 
1.1.3 Thrombosis Embolization in Atrial Fibrillation 
The blood stasis in the left atrial appendage, the endothelic dysfunction and the 
hypercoagulability of the blood interact synergically maintaining a pro-thrombotic state in AF.10 
The left atrial appendage is, in particular, the origin of 90% of the clinically-relevant thrombus 
formations in AF.22 Thrombus formations originated in the left atrium appendage can embolize 
to the circulation, and get carried towards the brain, where they can block small arteries.23 The 
occlusion of brain arteries can interrupt the blood flow, triggering an ischemic stroke or a 
transient ischemic attack, if the blood supply is quickly restored.23 
This pathogenesis explains the increased risk of stroke and other thromboembolic events 
associated with AF. Specifically, AF is associated with a 5-fold increase in the risk of stroke, 
independently of age.3 The percentage of strokes that can be attributed to AF is 15% all age 
groups, and 24% in patients older than 80 years.24,25 In elderly patients, AF is the most important 
single cause of ischemic stroke.23 
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1.1.4 Clinical and Economic Burden of Stroke 
Stroke ranks as the second leading cause of mortality in the world population, and it is 
responsible for around 10% of deaths worldwide.26 Every year, there are around 780,000 strokes 
in the US, 600,000 of which are first time strokes.27 The 30-day case fatality rate of stroke has 
been estimated between 16-23%.27,28 In the US, around 140,000 people die annually from 
stroke.29  
Stroke is the third most common cause of disability in high-income countries, accounting 
for 4 million disability-adjusted life years (DALYs).26 Stroke survivors present high rates of 
functional impairment,30 recurrent strokes,31 dementia,32 and depression.33 In addition to the 
physical and cognitive impairment associated with stroke, stroke sequelae include sensory, 
communication and emotional deficits.34,35 As a result, stroke survivors require an intensive use 
of medical services. For instance, around 20% of stroke survivors require institutionalization in 
the first five 5 years following the occurrence of the stroke.36,37  
The intensity of the acute and post-acute medical care following a stroke explains the high 
medical expenditures associated with stroke. In the US, the total annual costs of stroke have been 
estimated at $65.5 billion, with medical costs accounting for 67% or $44billion.38 With only half 
of stroke survivors under 65 years old returning to work after experiencing a stroke, loss of 
productivity from stroke-related morbidity and mortality is responsible for the remaining 33%, or 
$22billion.38,39  
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1.2 ANTICOAGULATION THERAPY IN THE PREVENTION OF STROKE 
Antithrombotic therapy is crucial to the management of AF patients. Antithrombotic therapy 
may inhibit the platelet function (antiplatelet therapy), the plasmatic coagulation (anticoagulant 
therapy), or induce the lysis of a thrombus formation (thrombolytic therapy). This dissertation 
focuses on the study of anticoagulation therapy in the prevention of stroke in AF. 
1.2.1 Impact of Anticoagulation 
1.2.1.1 Reduction in Stroke Risk 
The clinical trials that evaluated the effectiveness of antithrombotic therapy with warfarin in the 
prevention of stroke, as compared to placebo were conducted in the 1990s.40-45 In these trials, 
warfarin therapy was found to reduce the risk of stroke by around 60%, irrespective of the 
baseline risk.40-46 More recent studies have confirmed that antithrombotic therapy with warfarin 
reduces by two-thirds the risk of stroke.47,48 In addition, warfarin therapy has been associated  
with less severe stroke events, as well as reduced post-stroke mortality.46,49 
1.2.1.2 Increase in Bleeding Risk 
The most important safety concern associated with the use of anticoagulation is the increased 
risk of bleeding. Bleeding events that require hospitalization or involve sensitive locations are of 
special concern. Associated with the highest rates of mortality and disability, intracranial 
hemorrhages are specifically the most threatening type of bleeding events.50 The annual risk of 
intracranial bleeding for AF patients on anticoagulation has been estimated between 0.2 and 0.4 
 6 
percent.48 The incidence of major bleeding events involving other anatomical locations has been 
estimated at around 4 percent.48 
1.2.2 Assessment of Individual Patient Risk 
Because of the increased risk of bleeding events associated with the use of oral anticoagulation, 
the assessment of the risk of stroke and the risk of bleeding is crucial before the prescription of 
oral anticoagulation. There is solid evidence supporting the benefit-risk ratio of anticoagulation 
in patients with moderate to high risk of stroke.46,51,52 However, the risk of bleeding can 
outweigh the benefits of stroke risk reduction in low-risk patients.53 Several risk prediction 
models are available to estimate the thromboembolic risk and the risk of bleeding in patients 
with AF. 
1.2.2.1 Estimating Thromboembolic Risk 
CHADS2 Score 
CHADS2 score is a prediction tool that measures the risk of stroke in patients with AF. It was 
developed in 2001 on the basis of two previous risk scores: AFI and SPAF.54 Validated in a 
national sample of Medicare beneficiaries with AF, CHADS2 score is composed of five 
independent risk factors: congestive heart failure (CHF), hypertension, age of 75 years or older, 
diabetes, and a history of previous stroke or transient ischemic attack (TIA) (Table 1-1). All risk 
factors are assigned one point, except for a history of previous stroke or TIA, which is assigned 
two points.54  
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Before 2014, CHADS2 score was the prediction tool used by the American Heart 
Association (AHA), American College of Cardiology (ACC) and Heart Rhythm Society (HRS) 
in their clinical recommendations for anticoagulation in AF.55,56 Specifically, the AHA, ACC and 
HRS recommended the use of oral anticoagulation in patients with CHADS2 score equal or 
greater than two.56 
Table 1-1: Risk Factors in CHADS2 and CHA2DS2-Vasc Scores. 
Risk factor
CHADS2 
Points
CHA2DS2-
VASC Points
Congestive Heart Failure 1 1
Hypertension 1 1
Age ≥ 75 years 1 2
Diabetes Mellitus 1 1
History of Stroke or TIA or Thromboembolism 2 2
Vascular disease N/A 1
Age 65-74 years N/A 1
Sex category (Female gender) N/A 1  
CHA2DS2-Vasc Score 
Developed on the basis of the Euro Heart Survey on AF, CHA2DS2-Vasc score is a prediction 
tool that measures of the risk of stroke in AF patients.57 To calculate the CHA2DS2-Vasc score 
for a given patient, female sex, age between 65 and 74, congestive heart failure, hypertension 
history, vascular disease history and diabetes mellitus are assigned one point, and age of 75 or 
older and a history of previous stroke, TIA or thromboembolism are assigned two points (Table 
1-1).57  
Because CHA2DS2-Vasc score showed to be superior to CHADS2 score in defining the 
risk of stroke,58,59 the AHA, ACC and HRS commenced to use CHA2DS2-VASc score in their 
recommendations for the prescription of anticoagulation in 2014. Specifically, the AHA, ACC 
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and HRS currently recommend the use of oral anticoagulation in patients with CHA2DS2-VASc 
score equal or greater than two.60  
1.2.2.2 Estimating Bleeding Risk 
ATRIA Score 
Defined on the basis of the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) 
study, the ATRIA score is a prediction tool of the risk of major bleeding in AF patients on 
warfarin therapy.61 In calculating the ATRIA score, severe renal disease and anemia are each 
assigned three points, age of 75 or greater is assigned two points, and hypertension and a history 
of bleeding are each assigned one point (Table 1-2).61  
Patients with ATRIA score greater than five are at high risk of bleeding, patients whose 
ATRIA score equals four are at intermediate risk of bleeding, and those with ATRIA score lower 
than 4 are at low risk of presenting with major bleeding events.62 
Table 1-2: Risk Factors in ATRIA and HAS-BLED Scores. 
Risk factor ATRIA Points HAS-BLED Points
Hypertension 1 1
Renal disease 3 1
Abnormal liver function N/A 1
History of Stroke N/A 1
History of Bleeding or Predisposition to 
Bleeding
1
1
Labile INR N/A 1
Age > 65 years N/A 1
Age > 75 years 2 N/A
Concomitant Use of Aspirin or NSAIDs N/A 1
History of Alcohol or Drug Abuse N/A 1
Anemia 3 N/A  
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HAS-BLED Score 
HAS-BLED score is a prediction measure of the risk of major bleeding in AF patients on oral 
anticoagulation.61 It was defined on the basis of the Stroke Prevention Using an ORal Thrombin 
Inhibitor in Atrial Fibrillation (SPORTIF) clinical trial data, and it includes nine risk factors, 
each of which are assigned one point: hypertension, renal disease, liver disease, a history of 
stroke, a history of bleeding or predisposition to bleeding, labile international normalized ratio 
(INR), age of 65 or greater, use of antiplatelet agents or of nonsteroidal anti-inflammatory drugs 
(NSAIDs), and alcohol or drug use (Table 1-2).61  
Patients with HAS-BLED equal or greater than three are at elevated risk of bleeding, 
patients with HAS-BLED score one or two have a moderate risk of bleeding, and those whose 
HAS-BLED score equals zero have a low risk for bleeding events.62 Because HAS-BLED score 
has shown to be superior to ATRIA in the prediction of the risk of bleeding,62-64 it is the most 
commonly used score in the assessment of the risk of bleeding in patients with AF.  
Contrary to CHADS2, CHA2DS2-Vasc, and other prediction tools of the thromboembolic 
risk, ATRIA and HAS-BLED scores are not used to assess whether a patient should initiate 
anticoagulation therapy, but rather to identify those patients who should use anticoagulants with 
special caution and those with modifiable risk factors for bleeding.62 
1.2.3 Pharmacotherapy of Oral Anticoagulation 
1.2.3.1 Vitamin K Antagonists 
Vitamin K antagonists inhibit the vitamin K epoxide reductase, and thus the synthesis of vitamin 
K-dependent coagulation factors, including Factors II, VII, IX, X, and proteins C and S (Figure 
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1-1).65 From a structural perspective, most Vitamin K antagonists are coumarin derivatives; 
being warfarin the most commonly used vitamin K antagonist in the US.66 
 
Figure 1-1: Sites of Action of Anticoagulants in the Coagulation Cascade. 
 
Predominantly metabolized by the CYP2C9, warfarin has a highly-variable 
pharmacokinetic profile, with wide inter-individual variability.67 As a result, warfarin dosing is 
personalized for each patient (Table 1-3).67 Specifically, warfarin dose-adjustment is based on 
the routine blood monitoring of the prothrombin time or the INR. For patients with AF, the 
AHA, ACC and HRS recommend a target INR of 2-3.60 In addition, warfarin presents multiple 
interactions with other medications and food, which also increases the variability of warfarin 
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dose-response.67 In case of emergency, vitamin K can be administered as an antidote to reverse 
the anticoagulation effects of warfarin.68 
Warfarin has been consistently shown to reduce the risk of stroke by over 60%;46 however, 
warfarin therapy is associated with a high risk of hemorrhagic events and especially of 
intracranial bleeding, the most threatening bleeding event.50 
Table 1-3: Summary of the Pharmacokinetic Profile of Oral Anticoagulants. 
Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of 
Action
Vitamin K epoxide 
reductase inhibitor
Direct thrombin 
inhibitor
Direct factor Xa 
inhibitor
Direct factor Xa 
inhibitor
Direct factor Xa 
inhibitor
Elimination
Predominant hepatic 
metabolism via 
CYP2C9
Predominant renal 
elimination 
2/3 metabolic 
degradation via 
CYP3A4 and 
CYP2J2, 1/3 renal 
excretion
Multiple pathways: 
Hepatic metabolism 
via CYP3A4/5, and 
renal, intestinal and 
biliary excretion
Renal and 
intestinal 
excretion
Half-life 20-60 h 12-17 h 11-13 h 9-14 h 9-11 h
Frequency of 
Administration
Once a day Twice a day Once a day Twice a day Once a day
Interactions Multiple interactions
P-gp inhibitors and 
inducers
CYP3A4 and P-gp 
inhibitors and 
inducers
CYP3A4 and P-gp 
inhibitors and 
inducers
P-gp inhibitors 
and inducers
Antidote Vitamin K Idarucizumab Adaxanet alfa 
(Phase III)
Adaxanet alfa 
(Phase III)
Adaxanet alfa 
(Phase III)
Prodrug No Yes No No No
Monitoring INR monitoring None None None None  
1.2.3.2 Non-vitamin K Antagonist Oral Anticoagulants 
For decades, vitamin K antagonists were the only oral anticoagulants available to prevent stroke 
and systemic embolism in AF patients. Approved by the Food and Drug Administration (FDA) 
in 2010, the oral direct thrombin inhibitor dabigatran was the non-vitamin K antagonist oral 
anticoagulants (NOAC) available as an alternative to warfarin.69 One year later, rivaroxaban, a 
factor Xa inhibitor, gained approval for the same indication.70 The market entry of rivaroxaban 
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was followed by the approval of two new factor Xa inhibitors: apixaban in December 2012 and 
edoxaban in January 2015.71,72 
Mechanism of Action and Pharmacokinetics of NOACs 
Dabigatran is a competitive and reversible direct inhibitor of thrombin that binds to its active site 
(Table 1-3).73 The inhibition of thrombin prevents the conversion of fibrinogen intro fibrin, and 
the subsequent amplification of the coagulation, cross-linking of fibrin and activation of platelets 
(Figure 1-1).73Dabigatran is administered as dabigatran etexilate, a prodrug that is converted to 
its active form, dabigatran, by serine esterases (Table 1-3).74 Because dabigatran absorption is 
acid-dependent, dabigatran is formulated in capsules with tartaric acid to reduce the variability in 
its absorption.75 Dabigatran is predominantly cleared by the kidneys, and it is a P-glycoprotein 
substrate.73 As a result, it interacts with strong P-glycoprotein inducers or inhibitors.76 
Dabigatran is administered twice a day, and its half-life has been estimated at 12-17h.75 In 
October 2015, five years after dabigatran approval, idarucizumab, a dabigatran-binding 
monoclonal antibody fragment, was approved by the FDA to reverse the effects of dabigatran in 
emergency situations.77 
Rivaroxaban is an reversible direct Factor Xa inhibitor (Figure 1-1).78 Rivaroxaban inhibits 
both free Factor Xa and Factor Xa in the prothrombinase complex, thus decreasing the 
generation of thrombin.79 Rivaroxaban undergoes hepatic degradation via CYP3A4 and CYP2J2, 
with one third of rivaroxaban excreted by the kidneys.78 Substrate of the P-glycoprotein as well, 
its concurrent administration with CYP3A4 and P-glycoprotein inhibitors and inducers is 
contraindicated.70 The half-life of rivaroxaban is 11-13h; however, it follows once a day 
administration.80 There are currently no antidotes available to revert the effects of rivaroxaban 
and other factor Xa inhibitors, but the safety and efficacy of andexanet alfa, a modified Factor 
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Xa molecule that reverses the effects of the Factor Xa inhibitors, is being tested in phase III 
clinical trials.81  
Apixaban is a direct highly-selective inhibitor of Factor Xa (Figure 1-1).82 Similar to 
rivaroxaban, it binds both free Factor Xa and the prothrombinase complex.82 Apixaban is 
eliminated through multiple pathways, including hepatic metabolism via CYP3A4 and CYP3A5, 
renal excretion, intestinal and biliary elimination (Table 1-3).82 Also a substrate of the P-
glycoprotein, it interacts with CYP3A4 and P-glycoprotein inhibitors and inducers.71 Apixaban is 
administered twice a day, and its half-life has been estimated at 9-14h.80 
Edoxaban is an oral direct highly-selective inhibitor of the factor Xa (Figure 1-1). 83 
Similar to rivaroxaban and apixaban, it inhibits both free and clot-bound factor Xa.84 Edoxaban 
has a half-life of 9-11h,85 it is administered once a day, and it is predominantly excreted 
unchanged in feces and urine (Table 1-3).86 Because edoxaban is a substrate of P-glycoprotein 
and because metabolic degradation is a minor pathway of elimination of edoxaban, the plasmatic 
levels of edoxaban are highly influenced by the concomitant administration of P-glycoprotein 
inducers and inhibitors.87 
Clinical Trials Design and Results 
The approval of dabigatran was based on the results of the Randomized Evaluation of Long-
Term Anticoagulation Therapy (RE-LY) clinical trial.88 The RE-LY trial was a prospective, non-
inferiority, randomized clinical trial that compared dabigatran 150mg and dabigatran 110 mg 
with warfarin.88 In this study, dabigatran 150mg was found to be more efficacious in the 
prevention of stroke than warfarin, but similar in the risk of bleeding (Table 1-4).88 Dabigatran 
110mg, in contrast, was associated with similar rates of stroke, but lower incidence of major 
bleeding (Table 1-4).88  
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Table 1-4: Summary of the Results of the RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 
Trials 
New Oral 
Anticoagulant Dose Stroke prevention Bleeding risk
75 mg Not evaluated in 
RE-LY trial
Not evaluated in 
RE-LY trial
110 mg Similar Lower
150 mg Superior Similar
Rivaroxaban 15 mg if CrCl 15-50 mL/min, 20 mg if CrCl> 50mL/min Similar Similar
Apixaban
2.5mg if two of the following characteristics: age ≥ 
80 yrs, body weight ≤60 kg or serum Cr ≥ 1.5 mg/dL, 
5mg otherwise
Superior Lower
30 mg Similar Lower
60 mg Similar Lower
Edoxaban
Dabigatran
 
 
Rivaroxaban was approved based on the results of the Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial, a prospective, double-blind, non-
inferiority randomized clinical trial that compared rivaroxaban 20 mg/rivaroxaban 15mg in 
patients with creatinine clearance 30-49mL/min to warfarin.89 In this clinical trial, rivaroxaban 
showed to be similar to warfarin in both the prevention of stroke and the risk of bleeding (Table 
1-4).89  
The efficacy and safety of apixaban was compared to that of warfarin in the Apixaban for 
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) 
trial, a double-blind randomized non-interiority clinical trial.90 Subjects randomized to the 
apixaban group received the 2.5mg dose if they presented at least two of the following 
characteristics: age greater than 80, body weight lower than 60kg or serum creatinine greater 
than 1.5mg/dL. Otherwise, they were treated with apixaban 5mg. In this trial, apixaban showed 
to be superior in the prevention of stroke than warfarin, with a lower risk of major bleeding 
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(Table 1-4).90 Up to this date, apixaban is the only non-vitamin K antagonist oral anticoagulant 
to have showed superiority to warfarin in both efficacy and safety, and the only one to show a 
benefit in terms of survival.82,90  
The efficacy and safety of edoxaban 30mg and 60mg was compared to that of warfarin in 
the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–
Thrombolysis in Myocardial Infarction (ENGAGE AF-TIMI) trial.91 In this clinical trial, both 
edoxaban 30mg and edoxaban 60mg showed to be similar to warfarin in the prevention of stroke, 
but with lower rates of major bleeding (Table 1-4).91  
FDA Approval 
Based on the results of the RE-LY trial, the FDA approved dabigatran 150mg for the prevention 
of stroke and systemic embolism in AF patients with normal renal function (Table 1-5).69 Based 
only on pharmacokinetic data, the FDA approved dabigatran 75mg for the same indication, but 
for patients with creatinine clearance lower than 30 mL/min (Table 1-5).92 The FDA did not 
approve dabigatran 110mg, which was however approved by the European Medicines Agency, 
the Australian Therapeutic Goods Administration, and the Japanese Ministry of Health, Labor 
and Welfare.93-95 In the countries where dabigatran 110mg is available, it is indicated in the 
treatment of patients with AF older than 80 years, with high risk of bleeding or with 
gastrointestinal irritation.93-95 In October 2015, the FDA approved dabigatran 110mg for the 
prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip replacement 
surgery (Table 1-5).96 Nevertheless, dabigatran 110mg has not been approved in the US for the 
prevention of stroke and systemic embolism in AF.  
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Table 1-5: Dosage Recommendations for Non-Vitamin K Antagonist Oral Anticoagulants. 
New Oral 
Anticoagulant Dose FDA-Approved Indications  Subgroup of Patients
75 mg AF CrCl 15-30 mL/min
110 mg
Prophylaxis of DVT and PE following hip 
replacement surgery CrCl > 30 mL/min
AF CrCl > 30 mL/min
Reduction of risk of recurrent DVT and PE CrCl > 30 mL/min
Treatment of DVT and PE CrCl > 30 mL/min
10 mg
Prophylaxis of DVT and PE following hip 
or knee replacement surgery N/A
AF CrCl 15-49 mL/min
Treatment of DVT and PE N/A
AF CrCl > 50 mL/min
Reduction of risk of recurrent DVT and PE N/A
AF
Patients with two of the following 
characteristics age ≥ 80 yrs, body weight 
≤60 kg or serum Cr ≥ 1.5 mg/dL
Reduction of risk of recurrent DVT and PE
Prophylaxis of DVT following hip or knee 
replacement surgery
AF
Patients not included under 2.5 mg 
recommendations
Treatment of DVT and PE After 1 week on 10 mg
10 mg Treatment of DVT and PE Initial week
AF CrCl 15-50 mL/min
Treatment of DVT and PE 
CrCl 15-50 mL/min, or body weight ≤60 kg, 
or using P-gp inhibitors
AF CrCl 50-95 mL/min
Treatment of DVT and PE
Patients not included under 30 mg 
recommendations
Edoxaban
30 mg
60 mg
150 mg
Dabigatran
20 mg
15mgRivaroxaban
Apixaban
2.5 mg
5 mg
 
 
 
The FDA approved rivaroxaban 20mg and 15mg for the prevention of stroke and systemic 
embolism in AF in November 2011.70 Mirroring the dosing regimens evaluated in the ROCKET-
AF trial, the 15mg strength was approved for patients with creatinine clearance lower than 50 
ml/min (Table 1-5).70 In addition, there is another dose of rivaroxaban available, 10 mg, which is 
indicated in the prophylaxis of venous thromboembolism (VTE) following hip or knee 
replacement surgery.70,97 
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Following the review of the ARISTOTLE trial data, the FDA approved apixaban 5mg and 
2.5mg for the prevention of stroke and systemic embolism in AF patients in December 2012.71 In 
addition, apixaban 10mg is indicated in the initial treatment of DVT and PE (Table 1-5).71 Other 
approved indications of apixaban 2.5 mg include the reduction of risk of recurrent DVT and PE, 
and the prophylaxis of DVT in patients undergoing hip or knee replacement surgery.71 
In January 2015, the FDA approved edoxaban 30mg in the prevention of AF-related stroke 
in patients with creatinine clearance 15-50 mL/min, and edoxaban 60mg in those with creatinine 
clearance 50-95 mL/min (Table 1-5).72 In addition, edoxaban is approved for the treatment of 
DVT and PE (Table 1-5).72 
Evidence from Indirect Comparisons of Clinical Trials Data  
With the RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI trials comparing non-
vitamin K antagonist oral anticoagulants to warfarin, no clinical trials have directly compared the 
efficacy and safety of NOACs. In this scenario, some researchers used the results of the RE-LY, 
ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI clinical trials to predict how the risk of 
stroke and the risk of bleeding compare among NOACs. In these indirect comparisons, no 
differences were predicted in the efficacy of apixaban and dabigatran 150mg.98,99 However, 
rivaroxaban was predicted to be less effective in the prevention of stroke than dabigatran 150mg, 
and similar in the risk of bleeding.98,100,101 In addition, apixaban was associated with lower rates 
of major bleeding than dabigatran or rivaroxaban.99 Because the validity of indirect comparisons 
is strongly limited by inter-trial population differences, it is important to confirm these results 
with head-to-head analyses. 
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Evidence from Observational Studies 
Numerous observational studies have compared the incidence of stroke and bleeding with 
dabigatran or rivaroxaban and warfarin, finding conflicting results on the comparative 
effectiveness of dabigatran and warfarin.102-109 Using data from a US nationally representative 
cohort of Medicare beneficiaries, Graham et al. associated dabigatran with higher effectiveness 
in stroke prevention than warfarin;106 however, Larsen and colleagues found no differences in the 
prevention of stroke between warfarin and dabigatran in a Danish cohort.102 With regards to 
safety, dabigatran and rivaroxaban have been associated with similar rates of major bleeding than 
warfarin, but lower rates of intracranial bleeding.102,103,110 
To the best of our knowledge, no observational studies have compared head-to-head the 
real-world effectiveness of dabigatran and rivaroxaban in the prevention of stroke in AF. 
Furthermore, only one observational study has directly compared the incidence of hemorrhagic 
events between dabigatran and rivaroxaban.107 In this study, Sherid et al. used medical records 
from only two hospitals and did not examine the risk of bleeding by dose of anticoagulant 
separately.107 Because the risk of bleeding varies by the strength of anticoagulant, it is necessary 
to separately examine the risk of bleeding by dose.105,111,112  
After experiencing a major hemorrhage, clinicians need to assess whether a patient should 
resume anticoagulation therapy. Patients experiencing a major hemorrhage are at higher risk for 
presenting recurrent bleeding events;113 however, the interruption of anticoagulation has been 
associated with higher risk of thromboembolic events.114-117 This clinical decision whether a 
patient should restart anticoagulation after a major bleeding event is especially uncertain because 
patients at high risk of bleeding are also at high risk of stroke.118 Furthermore, there are no 
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specific clinical guidelines to inform the prescription of anticoagulants after a major bleeding 
event.60   
Using data from a health system in Michigan, Qureshi et al., estimated that around 51% of 
AF patients who experienced a major gastrointestinal bleeding on warfarin ceased 
anticoagulation after the bleeding event.114 However, no one has evaluated the patterns of NOAC 
use after a major bleeding event. In addition, some studies have compared the clinical outcomes 
of patients restarting and interrupting anticoagulation therapy with warfarin after a major 
bleeding event;114-117 nevertheless, none of them have done so for the case of NOACs. Because 
the prescription patterns, therapeutic management and bleeding profile of NOACs differ 
substantially from those of warfarin,92,119 it is important to separately compare the risks of stroke 
and recurrent bleeding events among patients who interrupt anticoagulation after a major 
bleeding event, and those who resume anticoagulation therapy with warfarin and with NOACs.  
Evidence from Cost-Effectiveness Analyses 
NOACs present certain advantages over traditional anticoagulant therapy with warfarin, such as 
fewer interactions and no requirement for routine monitoring of laboratory coagulation markers. 
However, NOACs are considerably more costly than warfarin: In 2012, the Medicare gross cost 
for one-month supply of dabigatran and rivaroxaban was $2731 and $2889, compared to $162 
for warfarin. As a result, it is important to compare the cost-effectiveness of NOACs and that of 
warfarin in the prevention of stroke and systemic embolism in AF.  
Table 1-6 shows a summary of the studies that have examined the cost-effectiveness of 
NOACs and warfarin in the prevention of stroke and systemic embolism in AF from the US 
perspective.120-129 Specifically, three studies have simultaneously compared the cost-
effectiveness of apixaban rivaroxaban, dabigatran and warfarin from the US perspective, finding 
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conflicting results.126-128 Whereas Canestaro et al. and Harrington et al. found that apixaban was 
a cost-effective strategy compared to dabigatran, Coyle and colleagues found that dabigatran was 
more effective and less costly than apixaban.126-128   
Table 1-6: Summary of Cost-Effectiveness Analysis for Non-Vitamin K Antagonist Oral Anticoagulants and 
Warfarin. 
Study Treatments Evaluated Results
ICER of dabigatran 150 mg vs warfarin 
=$45,372/QALY
ICER of dabigatran 110 mg vs warfarin 
=$51,229/QALY
ICER of dabigatran 150 mg vs warfarin 
=$86,000/QALY
ICER of dabigatran 110 mg vs warfarin 
=$150,000/QALY
Kamel et al., Neurology 2012 Apixaban and warfarin ICER of apixaban vs warfarin=$11,400/QALY
Kamel et al., Stroke 2012 Dabigatran and warfarin ICER of dabigatran vs warfarin=$25,000/QALY
Lee et al., Am J Cardiol 2012 Rivaroxaban and warfarin ICER of rivaroxaban vs warfarin=$27,498/QALY
Lee et al., Plos One 2012 Apixaban and warfarin Apixaban dominates warfarin
Canestaro et al., Circ Cardiovasc 
Qual Outcomes 2013
Apixaban 5mg, rivaroxaban 
20mg, dabigatran 150 mg and 
warfarin
ICER of apixaban vs warfarin=$93,063/QALY
Coyle at al., Value Health 2013 Apixaban, rivaroxaban 
dabigatran and warfarin
ICER of dabigatran vs warfarin=$20,787/QALY
 ICER of apixaban vs dabigatran =$64,600/QALY
ICER of dabigatran vs rivaroxaban=$53,067/QALY
ICER of rivaroxaban vs warfarin=$3190/QALY
Clemens et al., Am J Cardiol 2014 Dabigatran and warfarin ICER of dabigatran vs warfarin=$56,131/QALY
Apixaban, rivaroxaban 
dabigatran and warfarinHarrington et al., Stroke 2013
Dabigatran 150mg, dabigatran 
110mg and warfarin Shah et al., Circulation 2011
Freeman et al., Ann Intern Med 
2011
Dabigatran 150 mg, dabigatran 
110mg, and warfarin
 
 
Because edoxaban was recently approved, only three cost-effectiveness studies have 
examined the cost-effectiveness of this agent.130-132 These studies, all of which were performed 
from the European perspective, found that edoxaban was cost-effective when compared to 
warfarin,132 but it was not favored when compared to apixaban.131 Because the cost-effectiveness 
of NOACs is highly sensitive to pricing, and the prices of NOACs are considerably higher in the 
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US than in Europe, the results of cost-effectiveness analysis performed from the European 
perspective are not generalizable to the US.128  
Synthesis of the Evidence on NOACs: What We Know 
• On the comparative effectiveness and safety of dabigatran and rivaroxaban:   
o In indirect comparisons of clinical trials data, rivaroxaban was predicted to 
be less effective in the prevention of stroke than dabigatran 150mg, and 
similar in the risk of bleeding. 
o Only one observational study has directly compared the safety of 
rivaroxaban and dabigatran, finding no differences in the risk of bleeding 
between two NOACs. 
• On the use of anticoagulation after a major bleeding event: 
o Around 50% of the patients who have a major bleeding event on warfarin 
discontinue anticoagulation therapy. 
o The resumption of warfarin therapy after a major bleeding event is 
associated with increased survival and stroke-free survival, but higher risk 
of recurrent bleeding. 
•  On the cost-effectiveness of NOACS: 
o NOACs are a cost-effective strategy when compared to warfarin. 
o From the European perspective, apixaban is cost-effective when compared 
to edoxaban. 
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Gaps of Evidence on NOACs: What We Don´t Know 
• On the comparative safety and effectiveness of dabigatran and rivaroxaban: 
o It remains unclear whether there are differences in the risk of bleeding 
events with rivaroxaban and dabigatran. 
o The effectiveness of two doses of rivaroxaban and dabigatran in the 
prevention of stroke has never been directly compared.  
• On the use of anticoagulation after a major bleeding event: 
o The patterns of NOAC use after a major bleeding have never been 
evaluated. 
o It remains unknown whether the factors that affect post-hemorrhage 
resumption of anticoagulation are similar for warfarin and NOACS.  
o The effectiveness and safety outcomes associated with post-hemorrhage 
NOAC resumption, as compared to warfarin resumption or 
discontinuation of anticoagulation have never been compared. 
• On the cost-effectiveness of NOACS: 
o There is conflicting evidence on the comparative cost-effectiveness of 
dabigatran and apixaban.   
o The cost-effectiveness of edoxaban has never been compared to other 
NOACs from the US perspective. 
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1.3 OUTLINE AND RELEVANCE OF THE DISSERTATION  
This dissertation is composed of three research manuscripts that target each of the gaps of 
evidence identified on the  effectiveness, safety, and cost-effectiveness of the non-vitamin K 
antagonist oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban, and traditional 
warfarin therapy: 
Manuscript 1 (Chapter 2), entitled “Comparing Stroke and Bleeding with Rivaroxaban and 
Dabigatran in Atrial Fibrillation”, addresses the gap of evidence on the comparative safety and 
effectiveness of dabigatran and rivaroxaban. Specifically, it compares the risk of ischemic stroke, 
other thromboembolic events, all-cause mortality, major hemorrhage, intracranial bleeding, 
gastrointestinal bleeding, and any bleeding event with dabigatran and rivaroxaban, separately for 
high-dose (dabigatran 150mg and rivaroxaban 20mg) and low-dose initiators (dabigatran 75mg 
and rivaroxaban 15mg).  
Manuscript 2 (Chapter 3), entitled “Anticoagulant Use and Clinical Outcomes Following 
Major Hemorrhage on Dabigatran or Warfarin in Atrial Fibrillation” identified a cohort of AF 
patients who experienced a major bleeding event while using warfarin or dabigatran and 
followed them with two objectives: first, to evaluate the patterns of dabigatran and warfarin use 
after a first major bleeding event; and second, to compare the risk of ischemic stroke/all-cause 
mortality and recurrent hemorrhage between patients interrupting anticoagulation after a 
bleeding event and patients restarting warfarin or dabigatran.   
The data source for manuscripts 1 and 2 was pharmacy and medical claims in 2010-2013 
for a 5% random sample of Medicare Part D beneficiaries. These two studies have been 
approved by the Institutional Review Board at the University of Pittsburgh, and the Centers for 
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Medicare and Medicaid Services (CMS) have authorized the use of this data under Data User 
Agreement 27815. 
Addressing the gap of evidence on the comparative cost-effectiveness of NOACS from the 
US perspective, manuscript 3 (Chapter 4), entitled “Cost-Effectiveness of Non-Vitamin K 
Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation at High 
Risk of Bleeding”, compares the cost-effectiveness of apixaban 5mg, edoxaban 60 mg, 
rivaroxaban 20mg, dabigatran 150mg, dabigatran 110mg, and dose-adjusted warfarin in the 
prevention of stroke in a simulated cohort of 65-year old patients with AF and high risk of 
bleeding, defined by HAS-BLED score equal to or greater than 3. 
Chapter 5 summarizes the results from the three research manuscripts, provides an overall 
perspective for these findings, and elaborates on the public health significance of our research. 
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2.0  COMPARING STROKE AND BLEEDING WITH RIVAROXABAN AND 
DABIGATRAN IN ATRIAL FIBRILLATION 
2.1 ABSTRACT 
The objective of this manuscript was to compare the risk of stroke and bleeding after initiating 
rivaroxaban 20mg/dabigatran 150mg, or rivaroxaban 15mg/dabigatran 75mg among atrial 
fibrillation (AF) patients. Using 2010-2013 Medicare Part D data, we selected AF patients 
initiating dabigatran 150/75mg or rivaroxaban 20/15mg between November 4, 2011 (when 
rivaroxaban was approved) and December 31, 2013. Our sample included 7,322 dabigatran 
150mg users, 5,799 rivaroxaban 20mg users, 1,818 dabigatran 75mg users and 2,568 rivaroxaban 
15mg users. We followed them until stroke, other thromboembolic events, bleeding, 
discontinuation or switch of an anticoagulant, death, or December 31, 2013. We constructed Cox 
Proportional Hazard Models with propensity score weighting to compare the risk of stroke, other 
thromboembolic events, death, and bleeding between groups. We further examined the risk of 
stroke and bleeding in 3 subgroups: those 75 years or older, with chronic kidney disease, and 
with more than 7 concomitant comorbidities. We found no difference in the risk of stroke 
between dabigatran 150mg and rivaroxaban 20mg (hazard ratio [HR] 1.05, 95%CI 0.97-1.13) or 
between dabigatran 75mg and rivaroxaban 15mg (HR1.05, 95%CI 0.94-1.18). Compared to 
dabigatran 150mg, rivaroxaban 20mg was associated with higher risk of thromboembolic events 
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other than stroke (HR1.28, 95%CI 1.14-1.44), major bleeding (HR1.32, 95%CI 1.17-1.50), and 
death (HR1.36, 95% CI 1.19-1.56). The risk of thromboembolic events other than stroke 
(HR1.37, 95%CI 1.15-1.62), major bleeding (HR1.51, 95%CI 1.25-1.82) and death (HR1.21, 
95% CI 1.04-1.41) was also higher for rivaroxaban 15mg than dabigatran 75mg. Results from 
subgroup analyses were consistent with the overall sample.  In conclusion, there was no 
difference in stroke prevention between rivaroxaban and dabigatran; however, rivaroxaban was 
associated with a higher risk of thromboembolic events other than stroke, death and bleeding.  
2.2 INTRODUCTION 
Dabigatran 150mg and 75mg were approved by the US FDA in October 2010 for the prevention 
of stroke among AF patients, with 75mg indicated for patients with creatinine clearance lower 
than 30ml/min.96 Rivaroxaban 20mg and 15mg gained the FDA approval for the same indication 
in November 2011, with 15mg indicated for patients with creatinine clearance lower than 
50ml/min.70 Both doses of dabigatran are administered twice-a-day, whereas rivaroxaban follows 
a once-a-day regimen.70,96 Since the approval of rivaroxaban, two new NOACs have gained FDA 
approval for the same indication: apixaban in December 2012, and edoxaban in January 2015. 
71,72 
The RE-LY clinical trial found that dabigatran 150mg was similar to warfarin in the risk of 
bleeding, but superior in the prevention of stroke.88 Dabigatran 75mg was not evaluated in 
clinical trials, but approved only on the basis of pharmacokinetic studies.92 The results from the 
ROCKET-AF trial showed that rivaroxaban 20mg/15mg was similar to warfarin in both the risk 
of bleeding and the prevention of stroke.89,133 Because no clinical trials have directly compared 
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NOACs, previous researchers have used the results of the RE-LY88 and ROCKET-AF trials 89 to 
compare the effectiveness and safety of dabigatran and rivaroxaban.98,100  In these indirect 
comparisons, rivaroxaban 20mg/15mg was predicted to be less effective in the prevention of 
stroke and systemic embolism than dabigatran 150mg, but similar in the risk of bleeding.98,100 
Because the validity of indirect comparisons is limited by inter-trial population differences, and 
the subjects enrolled in the ROCKET-AF trial were considerably sicker than those in the RE-LY 
trial,88,89 it is important to perform direct analyses to compare the effectiveness and safety of 
dabigatran and rivaroxaban using the same population.  
Although several observational studies have compared the real-world effectiveness and 
safety of dabigatran or rivaroxaban with those of warfarin,102,104,109,134-136 only one study has 
directly compared the risk of bleeding between dabigatran and rivaroxaban, finding no 
differences in the risk of bleeding with two oral anticoagulants.107 However, the authors used 
medical records from only two hospitals and did not examine the risk of bleeding by dose of 
anticoagulant separately.107 Because the risk of bleeding varies by the strength of anticoagulant, 
it is also necessary to separately examine the risk of bleeding by dose.105,111,112 To the best of our 
knowledge, no observational studies have compared head-to-head the effectiveness of dabigatran 
and rivaroxaban in the prevention of stroke in AF. 
In this paper, we used 2010-2013 pharmacy and medical claims data from a 5% random 
sample of Medicare beneficiaries with AF to compare the risk of stroke, other thromboembolic 
events, death and bleeding following the initiation  of dabigatran and rivaroxaban, separately for 
high-dose (dabigatran 150mg and rivaroxaban 20mg) and low-dose initiators (dabigatran 75mg 
and rivaroxaban 15mg).  
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2.3 METHODS 
2.3.1 Data Source and Study Population 
We obtained 2010-2013 pharmacy and medical data for a 5% random sample of Medicare 
beneficiaries from CMS. First, we identified patients who filled a prescription for dabigatran or 
rivaroxaban between November 4, 2011 (the approval date for rivaroxaban) and December 31, 
2013 (n=44,621) (Figure 2-1). The index date was defined as the day of the first prescription 
filled for dabigatran or rivaroxaban in this time window. Second, we required that patients had a 
diagnosis of AF any time before the index date according to the CMS Chronic Condition 
Warehouse definition of AF (n=22,292).137 Third, we collected the pharmacy claims for oral 
anticoagulants filled during the three months before the index date and excluded patients who 
had a claim for dabigatran or rivaroxaban. We excluded them to make sure that we identified 
patients who initiated dabigatran or rivaroxaban treatment during our study period, when the risk 
of bleeding is higher.138 We used a three-month wash-out period because anticoagulants used in 
AF are usually prescribed as 30-day or 90-day supply prescriptions. Our final sample included 
7,322 dabigatran 150mg users, 5,799 rivaroxaban 20mg users, 1,818 dabigatran 75mg users and 
2,568 rivaroxaban 15mg users. In our study, we did not include rivaroxaban 10 mg users because 
this dose has not been approved for the prevention of stroke and systemic embolism in AF.70 
Since apixaban was approved in December 2012, the follow-up period available for this 
treatment group in our data set was shorter than one year and therefore, we did not include 
apixaban in our study. 
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Patients who filled a prescription for dabigatran or 
rivaroxaban between November 4, 2011 and 
December 31, 2013 (N=44,621)
Excluded: 22,329 had no diagnosis of AF 
before index date
Eligible sample 
(N=22,292)
Claims filled for oral 
anticoagulants three 
months before index date 
Excluded: 3,851 filled at least one claim for 
dabigatran or rivaroxaban
Eligible sample
(N=18,441)
Dabigatran 
150 mg (N=7,322) 
Dabigatran 
75 mg (N=1,816) 
Rivaroxaban    
20 mg (N=5,799) 
Rivaroxaban 
15 mg (N=2,568) 
Rivaroxaban 
10 mg (N=936) 
 
Figure 2-1: Selection of the Study Sample 
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We followed each individual from the index date until discontinuation of treatment, defined 
as a gap in anticoagulant treatment for over 60 days, switch of an anticoagulant or dose, death, or 
December 31, 2013.104 This study was approved by the Institutional Review Board at the 
University of Pittsburgh. 
2.3.2 Outcomes  
Effectiveness outcomes included ischemic stroke, other thromboembolic events and all-cause 
mortality. Ischemic stroke was defined as having one inpatient, emergency room or outpatient 
claim with primary or secondary International Classification of Diseases, Ninth Revision (ICD-
9) codes 433, 434 or 436.139,140 Other thromboembolic events included inpatient, emergency 
room or outpatient claims for systemic embolism (ICD-9=444), transient ischemic attack (ICD-
9=435) and pulmonary embolism (ICD-9=415.1). 139,140 Safety outcomes included any bleeding 
event and major bleeding; we also reported specifically safety outcomes for two anatomical 
locations: intracranial hemorrhage, and gastrointestinal bleeding. Major bleeding events included 
intracranial hemorrhage, hemoperitoneum, and inpatient or emergency room stays for 
gastrointestinal, hematuria, or not otherwise specified hemorrhage. The list of ICD-9 codes used 
to identify bleeding outcomes is in Table 2-1.  
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Table 2-1: International Classification of Diseases, Ninth Revision (ICD-9) Codes for Clinical Outcomes 
Event ICD-9 codes 
Ischemic Stroke 433, 434 or 436 
Systemic Embolism 444 
Transient Ischemic Attack 435 
Pulmonary Embolism  415.1 
Intracranial Bleeding 430, 431, 432 
Hemoperitoneum 568.81 
Hematuria 599.7 
Gastrointestinal Bleeding 
530.7, 531.0, 531.2, 531.4, 531.6, 532.0, 
532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 
533.6, 534.0, 534.2, 534.4, 534.6,569.3, 
535.01, 535.11, 535.21, 535.31, 535.41, 
535.51, 535.61, 535.71, 537.83, 537.84 , 
562.02 ,562.03, 562.12, 562.13, 569.85, 578 
Epistaxis 784.7 
Hemoptysis 786.3 
Vaginal Hemorrhage 623.8, 626.2 
Hemarthrosis 719.1, 719.2 
Not Otherwise Specified Hemorrhage 459 
  
2.3.3 Covariates 
We adjusted for demographic variables and clinical characteristics, all of which were measured 
on the index date. Demographic variables included age, race and Medicaid eligibility. Clinical 
characteristics included CHADS2 score,54 chronic kidney disease, hypertension, a history of 
stroke or TIA, prior acute myocardial infarction, diabetes, congestive heart failure, acquired 
hypothyroidism, number of other CMS priority comorbidities, a history of bleeding, concomitant 
use of NSAIDs, and concomitant use of antiplatelet drugs. CHADS2 score is a prediction 
measure of the risk of stroke in patients with atrial fibrillation. In the calculation of the CHADS2 
score, CHF, hypertension, age of 75 years or older and diabetes are assigned one point and a 
history of previous stroke or TIA is assigned two points; CHADS2 score is calculated as the sum 
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of all points.54 The number of other CMS priority comorbidities was calculated as the sum of 
previous a history of Alzheimer’s disease, related disorders or senile dementia, anemia, asthma, 
benign prostatic hyperplasia, cataract, chronic obstructive pulmonary disease, ischemic heart 
disease, hip or pelvic fracture, glaucoma, hyperlipidemia, osteoporosis, rheumatoid arthritis or 
osteoarthritis, breast cancer, colorectal cancer, prostate cancer, lung cancer and endometrial 
cancer. A history of bleeding was defined as having one claim with ICD-9 codes for any 
bleeding event in the year before the index date. Concurrent use of NSAIDS was defined as 
filling a prescription for diclofenac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, 
piroxicam, meloxicam, mefenamic acid or indomethacin after the index date; and concurrent use 
of antiplatelet drugs was defined as filling a prescription for aspirin, clopidogrel, prasugrel, 
dipyridamol, ticlopidine or ticagrelor after the index date. 
2.3.4 Statistical Analysis 
We compared patient characteristics between dabigatran 150mg initiators and rivaroxaban 20mg 
initiators (high-dose initiators), and between dabigatran 75mg initiators and rivaroxaban 15mg 
initiators (low-dose initiators) using chi-square tests. To compare the unadjusted cumulative 
incidence of effectiveness and safety outcomes at 1 year follow-up, we constructed Kaplan-
Meier time-to-event curves.  
One of the limitations from using observational data to conduct comparative-effectiveness 
studies is that individuals in one treatment group may not be comparable to individuals in the 
other group. To mitigate this problem, we used propensity score weighting, which was conducted 
in two steps. First, we constructed a logistic regression controlling for all covariates listed in the 
Covariates Section to calculate  the probability of initiating rivaroxaban (propensity score).We 
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used the Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG) in statistical 
software R to find the best logistic regression model to calculate the propensity score. We 
calculated standardized differences in covariate means between two treatment groups to evaluate 
whether covariates were balanced between treatment groups after propensity score weighting.141 
Standardized differences with absolute values below 10% indicate a good balance between 
treatment groups.142 Second, we constructed Cox Proportional Hazards models to compare 
effectiveness and safety outcomes between treatment groups, using the inverse of the propensity 
score for each individual as a weight. Cox models included one indicator variable for 
rivaroxaban initiation, as well as all pre-defined covariates listed in the Covariates Section. 
Because one of the limitations of this methodology is the presence of large weights, we checked 
the distribution of weights and found that none of the subjects had weights larger than 10. For all 
time-to-event analyses except for the ones that compared the risk of all-cause mortality between 
treatment groups, the time at risk was censored at the end of the study period (December 31, 
2013), or at switch of anticoagulant or dose, discontinuation of anticoagulant therapy, or death. 
Time-to-event analyses built to compare the risk of all-cause mortality between treatment groups 
had the same censoring events except death. All analyses were conducted with statistical 
software SAS 9.4 (Cary, NC). 
We further compared the effectiveness and safety of dabigatran and rivaroxaban among 
three subgroups of patients: those older than 75 years, with chronic kidney disease, or with at 
least 7 CMS priority conditions other than AF.143 Specifically, for each subgroup identified, we 
re-calculated the propensity score, and constructed Cox models to compare effectiveness and 
safety outcomes following the same methodology as with the overall sample. Cox models 
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controlled for all the covariates listed in the Covariates Section, except for the one defining the 
subgroup.  
2.3.5 Sensitivity Analyses 
One may argue that some of our study participants may have initiated anticoagulation therapy for 
an indication other than AF. To examine whether this may have affected our results, we collected 
the medical claims of study participants for venous thromboembolism (ICD-9 codes 452,453), 
pulmonary embolism (ICD-9=415.5), phlebitis (ICD-9=451), or undergoing hip or knee 
replacement surgery (ICD-9=V43.64, V43.64 or Healthcare Common Procedure Coding System 
(HCPCS) codes 27437, 27438, 27440–27443, 27445–27447, 27486, 27487, 27125, 27130, 
27132, 27134, 27137, 27138 and 27236) in the three months before the index date.144,145 
Specifically, 171 (2.3%) dabigatran 150mg users,  410 (7.1%) rivaroxaban 20mg users, 62 
(3.4%) dabigatran 75mg users and 281 (10.8%) rivaroxaban 15mg users had a medical claim 
with a diagnosis of these conditions. After excluding these individuals from the sample, we re-
calculated the propensity score and constructed Cox models following the same methodology as 
explained in the Statistical Analysis section. Subjects who used warfarin before the initiation of 
dabigatran or rivaroxaban may have had remaining warfarin at the time of dabigatran or 
rivaroxaban initiation. If they experienced a bleeding event soon after the initiation of dabigatran 
or rivaroxaban, the occurrence of such event may have been affected by the remaining warfarin. 
To analyze whether our results for the comparative risk of bleeding with two NOACs were 
affected by this problem, we ran our analyses after excluding subjects who filled a prescription 
for warfarin six months before index date. Specifically, 1453 (19.8%) dabigatran 150mg users, 
1828 (31.5%) rivaroxaban 20mg users, 424 (23.4%) dabigatran 75mg users and 769 (29.9%) 
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rivaroxaban 15mg users had filled a prescription for warfarin in the 6 months before index date 
and were therefore excluded from these sensitivity analyses. Because in patients with a history of 
stroke it is difficult in some occasions to differentiate new events from prior diagnoses of 
strokes, we conducted sensitivity analyses by including and excluding patients who had a history 
of stroke or TIA before the index date. 
2.4 RESULTS 
2.4.1 Patient Characteristics 
The mean follow-up period was 385 days for dabigatran 150mg users, 251 days for rivaroxaban 
20mg users, 357 days for dabigatran 75mg users, and 239 for rivaroxaban 15mg users (Table 2-
2).  
Table 2-2. Follow-up Period and Patterns of Anticoagulation Use, by Treatment and Dose. 
  
Dabigatran 150mg 
(N=7,322) 
Rivaroxaban 20mg 
(N=5,799) P-Value 
Follow-up period, mean (SD)  385 (247) 251 (177) <0.001 
Discontinuation (%) 13.4 5.1 <0.001 
Switch of treatments or dose (%) 14.9 3.4 <0.001 
  
Dabigatran 75mg 
(N=1,816) 
Rivaroxaban 15mg 
(N=2,568) P-Value 
Follow-up period, mean (SD)  357 (244) 239 (175) <0.001 
Discontinuation (%) 13.1 4.4 <0.001 
Switch of treatments or dose (%) 10.7 0.6 <0.001 
  
Table 2-3 shows the comparison of patient characteristics before and after propensity score 
weighting for high-dose and low-dose initiators. Before propensity score weighting, rivaroxaban 
20mg initiators were more likely to be also eligible for Medicaid benefits, have chronic kidney 
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disease and acquired hypothyroidism than dabigatran 150mg initiators. The mean age of 
dabigatran 150mg users was 75.64, and the mean age of rivaroxaban 20mg users was 75.44. 
Dabigatran 75mg users and rivaroxaban 20mg were 82.0 and 81.71 years old on average, 
respectively. The use of NSAIDs before propensity score weighting was higher among patients 
initiating dabigatran 150mg  (15.9%) than those initiating rivaroxaban 20mg (11.4%), p-
value<0.001.  Although low-dose dabigatran and rivaroxaban are only indicated in AF patients 
with reduced kidney function, only 52.6% of patients on dabigatran 75mg and 51.5% of those on 
rivaroxaban 15mg had a diagnosis of chronic kidney disease. After propensity score weighting, 
all patient characteristics were balanced between rivaroxaban and dabigatran groups for both 
high and low dose initiators.  
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Table 2-3: Baseline Characteristics of the Study Cohorts, Before and After Propensity Score Weighting, by Treatment and Dose 
 
Variable (%)
Dabigatran 
(N=7,322)
Rivaroxaban 
(N=5,799)
P-Value
Dabigatran 
(N=1,816)
Rivaroxaba
n 
(N=2,568)
P-Value D R
Standardized  
Difference in 
Covariate Means
D R
Standardized  
Difference in 
Covariate 
Means
Age 0.005 0.565
     <65 5.0 6.3 1.9 1.9 5.5 5.6 -0.7 1.9 1.9 -0.1
    65-74 39.3 38.4 14.4 15.5 38.9 38.9 0.1 14.6 14.9 -0.8
    ≥75 55.7 55.3 83.7 82.5 55.6 55.5 0.2 83.6 83.3 0.8
Male sex 49.5 45.9 <0.001 34.7 32.5 0.132 48.0 47.9 0.0 33.4 33.3 0.2
Race 0.058 0.894
     White 87.5 86.3 86.4 86.5 87.3 87.3 -0.2 87.1 86.8 0.6
     Black 5.4 5.5 5.6 5.1 5.4 5.3 0.4 5.2 5.2 0.0
     Asian 1.8 1.8 2.7 2.9 1.7 1.7 0.0 2.6 2.6 -0.4
     Hispanic 3.9 5.1 4.3 4.7 4.3 4.4 -0.3 4.3 4.5 -0.6
     Native American 0.3 0.3 0.3 0.3 0.2 0.2 0.0 0.3 0.3 0.4
     Other 1.2 1.1 0.7 0.6 1.1 1.1 0.5 0.5 0.6 -0.5
Medicaid eligibility 20.0 22.7 <0.001 27.3 25.9 0.314 21.0 20.9 0.3 26.2 26.3 -0.2
CHADS2 score--mean (SD) 3.28 (1.30) 3.29 (1.32) 0.961 3.87 (1.29) 3.79 (1.30) 0.039 3.28 (1.75) 3.28 (1.96) 0.0 3.83 (1.99) 3.83 (1.68) -0.4
CMS priority comorbidities 
     CKD 26.3 28.6 0.003 52.6 51.5 0.469 27.2 27.2 -0.1 51.9 51.8 0.1
     Hypertension 92.9 92.8 0.976 96.9 96.6 0.577 92.9 92.9 0.0 96.9 96.8 0.3
     Previous stroke or TIA 22.7 23.4 0.302 34.7 33.7 0.505 22.9 23.0 -0.2 34.3 34.1 0.3
     AMI 6.5 7.4 0.044 11.1 11.1 0.989 6.8 6.8 0.1 10.8 11.0 -0.7
     Diabetes mellitus 43.4 44.4 0.258 50.0 50.0 0.992 43.8 43.9 -0.2 50.1 50.0 0.0
     CHF 51.8 50.8 0.219 72.5 66.6 <0.001 51.3 51.3 0.0 69.3 69.1 0.5
     Acquired 
hypothyroidism 26.0 29.6 <0.001 38.2 39.5 0.410 27.6 27.7 -0.1 39.3 39.1 0.3
     No. of other CMS 
priority comorbidities <0.001 0.074
     0-3 22.4 21.5 8.8 7.0 22.0 21.9 0.2 7.8 7.6 1.0
     4-6 41.5 38.1 30.1 31.2 40.0 40.0 0.0 30.5 30.7 -0.5
     ≥7 36.2 40.4 61.1 61.8 38.0 38.0 -0.2 61.7 61.7 -0.1
History of bleeding 19.2 20.2 0.145 25.4 24.7 0.579 19.6 19.5 0.1 24.8 24.9 -0.3
Use of NSAIDs 15.9 11.4 <0.001 13.1 9.9 0.001 13.9 13.7 0.6 11.1 11.0 0.2
Use of antiplatelets 7.1 6.1 0.017 9.5 6.9 0.002 6.6 6.4 0.5 7.7 7.7 0.1
Before Propensity Score Weighting After Propensity Score Weighting
High Dose Low Dose High Dose Low Dose
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2.4.2 Unadjusted Incidence of Effectiveness and Safety Outcomes 
Table 2-4 shows the number of events and the unadjusted cumulative incidence rates of 
effectiveness and safety outcomes by treatment group. Dabigatran 150mg was associated with 
lower risk of all-cause mortality, major bleeding, gastrointestinal bleeding and any bleeding 
events than rivaroxaban 20 mg. However, there was no difference in the unadjusted risk of 
ischemic stroke, other thromboembolic events, and intracranial bleeding between dabigatran 
150mg initiators and rivaroxaban 20mg initiators. The unadjusted incidence of clinical outcomes 
did not differ between dabigatran 75mg and rivaroxaban 15mg initiators except for any bleeding 
event, which was higher with rivaroxaban 15mg than dabigatran75mg. 
Table 2-4. Number of Events and Cumulative Incidence Rates at 1 Year Follow-up of Clinical Outcomes, by 
Treatment Group and Dose. 
 
Number of events (%) 
 
Cumulative Incidence At 1 year (95% CI) 
High Dose 
Dabigatran 
(N=7,322) 
Rivaroxaban 
(N=5,799) 
 
Dabigatran (N=7,322) Rivaroxaban (N=5,799) 
Effectiveness Outcomes   
   Ischemic Stroke  1036 (14.2) 580 (10.0)  0.12 ( 0.11 , 0.13 ) 0.12 ( 0.11 , 0.14 ) 
Other Thromboembolic events 386 (5.3) 250 (4.3) 
 
0.041 ( 0.036 , 0.046 ) 0.053 ( 0.046 , 0.061 ) 
All-Cause Mortality 247 (3.4) 229 (3.9)  0.032 ( 0.030 , 0.039 ) 0.050 ( 0.043 , 0.056 ) 
Safety Outcomes      
Major Bleeding 349 (4.8) 229 (4.0)  0.034 ( 0.029 , 0.038 ) 0.050 ( 0.043 , 0.058 ) 
Any Bleeding 1658 (22.6) 1008 (17.4)  0.19 ( 0.18 , 0.20 ) 0.22 ( 0.21 , 0.23 ) 
Intracranial Bleeding 88 (1.2) 33 (0.6)  0.008 ( 0.006 , 0.010 ) 0.007 ( 0.004 , 0.009 ) 
Gastrointestinal Bleeding 722 (9.9) 439 (7.6)   0.08 ( 0.07 , 0.08 ) 0.10 ( 0.09 , 0.11 ) 
Low Dose 
Dabigatran 
(N=1,816) 
Rivaroxaban 
(N=2,568) 
 
Dabigatran (N=1,816) Rivaroxaban (N=2,568) 
Effectiveness Outcomes   
   Ischemic Stroke  316 (17.4) 315 (12.3)  0.16 ( 0.14 , 0.18 ) 0.17 ( 0.15 , 0.19 ) 
Other Thromboembolic events 130 (7.2) 161 (6.3) 
 
0.07 ( 0.06 , 0.08 ) 0.08 ( 0.07 , 0.09 ) 
All-Cause Mortality 146 (8.0) 191 (7.4)  0.087 ( 0.073 , 0.101 ) 0.099 ( 0.085 , 0.114 ) 
Safety Outcomes 
  
   
Major Bleeding 107 (5.9) 139 (5.4)  0.053 ( 0.041 , 0.064 ) 0.073 ( 0.060 , 0.087 ) 
Any Bleeding 429 (23.6) 518 (20.2)  0.21 ( 0.19 , 0.23 ) 0.27 ( 0.24 , 0.29 ) 
Intracranial Bleeding 26 (1.4) 29 (1.1)  0.013 ( 0.007 , 0.018 ) 0.018 ( 0.011 , 0.025 ) 
Gastrointestinal Bleeding 206 (11.3) 229 (8.9)   0.10 ( 0.08 , 0.11 ) 0.12 ( 0.10 , 0.13 ) 
 
 
Bold denotes statistical significant results. 
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2.4.3 Adjusted Hazard Ratio of Effectiveness and Safety Outcomes 
Figure 2-2 shows the adjusted hazard ratios for effectiveness and safety outcomes after 
propensity score weighting. The risk of ischemic stroke did not differ between rivaroxaban 20 
mg and dabigatran 150mg (HR 1.05; 95% CI 0.97-1.13); however, rivaroxaban 20mg was 
associated with higher risk of other thromboembolic events (HR 1.28; 95%CI 1.14-1.44) and all-
cause mortality (HR 1.36; 95% CI, 1.19-1.56) than dabigatran 150mg. The risk of major 
bleeding (HR 1.32; 95% CI, 1.17-1.50), any bleeding event (HR 1.17; 95% CI, 1.10-1.24) and 
gastrointestinal bleeding (HR 1.19; 95% CI, 1.03-1.30) was also higher among patients initiating 
rivaroxaban 20mg than those initiating dabigatran 150 mg. The risk of intracranial hemorrhage 
did not differ between high-dose dabigatran and rivaroxaban. 
Our results for the comparative risk of effectiveness and safety outcomes among low-dose 
initiators are consistent with the findings from high-dose initiators: There was no difference in 
the risk of ischemic stroke and intracranial bleeding between rivaroxaban 15mg and dabigatran 
75mg; however,  the risk of other thromboembolic events (HR 1.37; 95%CI, 1.15-1.62), all-
cause mortality (HR 1.21; 95% CI, 1.04-1.41), major bleeding (HR 1.51; 95% CI, 1.25-1.82), 
any bleeding event (HR 1.39; 95% CI, 1.27-1.53) and gastrointestinal bleeding (HR 1.25; 95% 
CI, 1.09-1.44) was higher with rivaroxaban 15mg than dabigatran 75mg.  
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0.5 0.5
Effectiveness Outcomes
     Ischemic Stroke 1.05 (0.97-1.13) 1.05 (0.94-1.18)
     Other Thromboembolic Events 1.28 (1.14-1.44) 1.37 (1.15-1.62)
     All-Cause Mortality 1.36 (1.19-1.56) 1.21 (1.04-1.41)
Safety Outcomes
     Major Bleeding 1.32 (1.17-1.50) 1.51 (1.25-1.82)
     Any Bleeding 1.17 (1.10-1.24) 1.39 (1.27-1.53)
     Intracranial Bleeding 0.82 (0.61-1.11) 1.23 (0.83-1.84)
     Gastrointestinal Bleeding 1.19 (1.09-1.30) 1.25 (1.09-1.44)
Rivaroxaban 20mg vs Dabigatran 150mg,  
Adjusted Hazard Ratio (95% CI)
Rivaroxaban 15mg vs Dabigatran 
75mg,  Adjusted Hazard Ratio (95% CI)
2 2  
Figure 2-2: Hazard Ratios for Effectiveness and Safety Outcomes, by Treatment and Dose 
 
2.4.4 Subgroup Analyses 
Our results for selected effectiveness and safety outcomes in three high-risk subgroups are 
consistent with the findings from the overall sample (Figure 2-3). Among patients older than 75 
years, with chronic kidney disease, or with more than 7 CMS priority conditions other than AF, 
rivaroxaban was consistently associated with higher risk of thromboembolic events other than 
stroke, major bleeding and any bleeding events, but similar risk of ischemic stroke than 
dabigatran.   
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Ischemic Stroke 1.06 (0.96-1.16) 1.06 (0.93-1.20)
Other Thromboembolic Events 1.45 (1.24-1.69) 1.40 (1.16-1.68)
Major Bleeding 1.30 (1.12-1.51) 1.35 (1.11-1.66)
Any Bleeding 1.17 (1.08-1.26) 1.39 (1.25-1.54)
Ischemic Stroke 0.98 (0.87-1.12) 1.13 (0.97-1.32)
Other Thromboembolic Events 1.29 (1.05-1.58) 1.17 (0.93-1.48)
Major Bleeding 1.34 (1.10-1.64) 1.48 (1.17-1.88)
Any Bleeding 1.17 (1.06-1.29) 1.34 (1.18-1.52)
Ischemic Stroke 1.12 (1.01-1.25) 1.05 (0.91-1.20)
Other Thromboembolic Events 1.55 (1.31-1.84) 1.39 (1.14-1.69)
Major Bleeding 1.31 (1.10-1.55) 1.30 (1.03-1.63)
Any Bleeding 1.14 (1.05-1.24) 1.34 (1.19-1.51)
Rivaroxaban 20mg vs Dabigatran 150mg,  
Adjusted Hazard Ratio (95% CI)
Rivaroxaban 15mg vs Dabigatran 75mg,  
Adjusted Hazard Ratio (95% CI)
> 75 yrs
Chronic Kidney Disease
More than 7 Concomitant Comorbidities
2 2
2 2
2 2
 
Figure 2-3: Hazard Ratios for Effectiveness and Safety Outcomes, by Subgroup, Treatment and Dose 
 
2.4.5 Sensitivity Analyses 
Tables 2-5, 2-6 and 2-7 show the results of the sensitivity analyses. After excluding patients with 
a diagnosis of an indication for anticoagulation other than AF, there was no difference in the risk 
of thromboembolic events other than stroke between rivaroxaban and dabigatran, but other 
outcomes were similar as those from the overall sample. After the exclusion of recent warfarin-
experienced subjects from the study sample, the hazard ratios of bleeding events did not vary 
much (Table 2-6). Finally, the exclusion of patients with a history of stroke or TIA did not 
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impact our results for the comparative risk of effectiveness outcomes between two oral 
anticoagulants (Table 2-7). 
 
Table 2-5: Hazard Ratios for Effectiveness and Safety Outcomes after Excluding Patients with a Diagnosis of 
Thromboembolic Events or Hip or Knee Replacement Surgery. 
  
Rivaroxaban 20mg vs 
Dabigatran 150mg,  Adjusted 
Hazard Ratio (95% CI) 
Rivaroxaban 15mg vs 
Dabigatran 75mg,  Adjusted 
Hazard Ratio (95% CI) 
Effectiveness Outcomes   
     Ischemic Stroke  1.05 (0.97-1.14) 1.04 (0.92-1.17) 
     Other Thromboembolic Events 1.13 (0.99-1.28) 0.93 (0.76-1.13) 
     All-Cause Mortality 1.33 (1.15-1.53) 1.19 (1.01-1.41) 
Safety Outcomes 
       Major Bleeding 1.30 (1.14-1.48) 1.49 (1.22-1.81) 
     Any Bleeding 1.17 (1.10-1.24) 1.40 (1.26-1.54) 
     Intracranial Bleeding 0.79 (0.59-1.08) 1.24 (0.81-1.88) 
     Gastrointestinal Bleeding 1.20 (1.10-1.31) 1.24 (1.07-1.43) 
  
Table 2-6: Hazard Ratios for Bleeding Events after Excluding Recent Warfarin-Experienced Subjects. 
  
Rivaroxaban 20mg vs 
Dabigatran 150mg,  Adjusted 
Hazard Ratio (95% CI) 
Rivaroxaban 15mg vs 
Dabigatran 75mg,  Adjusted 
Hazard Ratio (95% CI) 
     Major Bleeding 1.45 (1.25-1.69) 1.62 (1.29-2.02) 
     Any Bleeding 1.25 (1.17-1.34) 1.51 (1.35-1.69) 
     Intracranial Bleeding 0.94 (0.66-1.34) 1.37 (0.88-2.14) 
     Gastrointestinal Bleeding 1.24 (1.12-1.38) 1.32 (1.12-1.56) 
  
Table 2-7. Hazard Ratios for Effectiveness Outcomes after Excluding Patients with a History of Stroke or 
Transient Ischemic Attack. 
Rivaroxaban 20mg vs 
Dabigatran 150mg,  Adjusted 
Hazard Ratio (95% CI)
Rivaroxaban 15mg vs 
Dabigatran 75mg,  
Adjusted Hazard Ratio 
(95% CI)
Ischemic Stroke 1.00 (0.90-1.11) 1.05 (0.88-1.25)
 Other Thromboembolic Events 1.23 (1.04-1.45) 1.51 (1.18-1.94)
 All-Cause Mortality 1.53 (1.29-1.80) 1.27 (1.04-1.54)  
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2.5 DISCUSSION 
To the best of our knowledge, our study is the first to compare effectiveness and safety outcomes 
between dabigatran and rivaroxaban, separately by dose, among Medicare patients with AF. Our 
study yielded two main findings. First, we found no differences in stroke prevention between 
dabigatran and rivaroxaban; however, rivaroxaban was associated with higher rates of 
thromboembolic events other than stroke and all-cause mortality than dabigatran. Second, we 
observed that the risk of major bleeding, gastrointestinal bleeding and any bleeding events was 
higher with rivaroxaban than dabigatran, but there was no difference in the risk of intracranial 
bleeding between dabigatran and rivaroxaban.  
Previous researchers have conducted indirect comparisons of the results from the RE-LY 
and ROCKET-AF trials, predicting that dabigatran would be associated with a lower combined 
risk of stroke and systemic embolism than rivaroxaban (HR 1.35; 95% CI 1.02-1.78), but with a 
similar risk of ischemic stroke (HR 1.33; 95% CI 0.98-1.78), and a similar risk of bleeding (HR 
1.12; 95% CI 0.92-1.37).98,100 We found no difference in the risk of ischemic stroke with two 
NOACs (HR 1.05; 95% CI, 0.97-1.13), but we observed that the risk of thromboembolic events 
other than stroke (HR 1.28; 95% CI, 1.14-1.44) and of bleeding (HR 1.32; 95%CI, 1.17-1.50) 
was higher with rivaroxaban. The differences between our results for the comparative risk of 
bleeding with two NOACs and those reported in indirect comparisons may be explained by the 
difference in patient characteristics of subjects enrolled in two clinical trials.98,100 For example, 
55% and 62% of the subjects enrolled in the ROCKET-AF trial had a prior stroke/TIA and heart 
failure, compared to 20% and 35% of those enrolled in the RE-LY trial, respectively.88,89 Using 
US commercial insurance data, Laliberte et al. compared the effectiveness and safety of 
rivaroxaban and warfarin, estimating the annual risk of major bleeding on rivaroxaban at 
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3.3%.134 Our estimate for the rate of major bleeding on rivaroxaban 20mg (5%) is higher than the 
estimate reported by Laliberte and colleagues, partially because of the higher prevalence of risk 
factors for bleeding among our study sample. For instance, 28.6 % of our study participants on 
rivaroxaban 20mg had a diagnosis of kidney disease, whereas only 7.5% of those included in the 
study by Laliberte et al. did.134 To the best of our knowledge, only one study has directly 
compared the risk of bleeding with dabigatran and rivaroxaban. In doing so, Sherid et al. used 
medical records from two community hospitals and did not find differences in the risk of 
bleeding with two NOACs.107 However, the sample size of this study was very small (227 
dabigatran users and 147 rivaroxaban users), which may have prevented the authors from finding 
significant differences.  
Our study is subject to four main limitations. First, propensity score weighting did not 
adjust for unobserved patient characteristics, such as the result of laboratory tests, because they 
are not available in Medicare claims data. Thus, some unobserved risk factors for clinical 
outcomes may have been unbalanced between treatment groups, such as creatinine clearance. 
However, we balanced the proportion of patients with chronic kidney disease between treatment 
groups using propensity score weighting, and we also included this as a covariate in our Cox 
Proportional Hazards models. Second, because of the unavailability of data on INR, we could not 
calculate the  HAS-BLED risk score, which is a prediction tool of the risk of bleeding.113,146 
Nevertheless, we balanced all components of HAS-BLED score except for labile INR between 
treatment groups, and included them as separate covariates in our analytical models as well. 
Third, in our study, we used 2010-2013 Medicare data, so our study period represents the first 
two years after rivaroxaban entered the US market. Prescribing patterns of NOACs may change 
over time as prescribers become more familiar with these agents.105,112 Fourth, our study did not 
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include apixaban, which was approved in December 2012, because we would not have enough 
follow-up period to study effectiveness outcomes. As a result, it will be informative to repeat our 
analyses as newer Medicare Part D data becomes available, and compare the effectiveness and 
safety of dabigatran and rivaroxaban to those of apixaban. 
Our research has three main implications. First, because there was no difference in stroke 
prevention with two NOACs but dabigatran was superior in safety to rivaroxaban, the use of 
dabigatran should be preferred over rivaroxaban. One may argue, however, that the benefit 
associated with dabigatran might be counterbalanced by lower rates of adherence because of the 
twice-a-day regimen. In fact, a recent analysis of US commercial insurance claims data found 
that rivaroxaban users were more adherent than patients on dabigatran.147 Our study captured the 
real-world use of two new oral anticoagulants, where adherence to rivaroxaban is likely to be 
higher, and found no difference in the prevention of stroke with two new oral anticoagulants, yet 
rivaroxaban was associated with higher risk of bleeding. This implies that despite of the twice-a-
day regimen, dabigatran still presents a better benefit/risk ratio in the real-world clinical practice 
than rivaroxaban. Second, consistent with the results from the overall sample, we found that 
dabigatran was associated with lower rates of bleeding but similar risk of stroke than rivaroxaban 
among patients older than 75 years or with kidney disease.54,113 In these two subgroups of 
patients with high-risk of bleeding, dabigatran would be especially preferred compared to 
rivaroxaban because, in case of major hemorrhage, there are two strategies available to revert the 
effects of dabigatran that are not available for rivaroxaban: a FDA-approved antidote,77 and 
hemodialysis.148 Third, rivaroxaban 15mg and dabigatran 75mg are indicated in the prevention of 
stroke or systemic embolism in renally impaired patients with AF; however, half of the study 
participants who initiated rivaroxaban 15mg or dabigatran 75mg did not have a diagnosis of 
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chronic kidney disease. Our results suggest that low doses of anticoagulants were prescribed off-
labelly in 2011-2013 for patients who did not have chronic kidney disease, but who had however 
other risk factors for bleeding, such as hypertension, a history of stroke or a history of bleeding. 
These prescribing patterns may have been motivated by the concerns of severe bleeding events 
with NOACs, the unavailability of dabigatran 110mg in the US, and the lack of an antidote to 
reverse the anticoagulation effects of rivaroxaban and dabigatran in case of emergency in 2011-
2013, the period that our study represents. Idarucizumab, the specific antidote for dabigatran, 
was approved in October 2015.77  
In conclusion, we found that dabigatran was superior in safety to rivaroxaban; however, we 
did not find differences in stroke prevention between two oral anticoagulants. Our findings have 
important implications to the use of NOACs among AF patients. 
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3.0  ANTICOAGULATION USE AND CLINICAL OUTCOMES FOLLOWING 
MAJOR BLEEDING ON DABIGATRAN OR WARFARIN IN ATRIAL FIBRILLATION 
3.1 ABSTRACT 
Little is known about the patterns of anticoagulation use and clinical outcomes associated with 
the resumption of anticoagulation after a major hemorrhage.  This manuscript had two 
objectives: first, to evaluate the patterns of anticoagulation use after a first major bleeding event 
on warfarin or dabigatran; and second, to compare the combined risk of ischemic stroke and all-
cause mortality and recurrent hemorrhage between patients interrupting anticoagulation after a 
bleeding event and patients restarting warfarin or dabigatran.  Using 2010-2012 Medicare Part D 
data, we identified atrial fibrillation patients who experienced a major bleeding while using 
warfarin (n=1135) or dabigatran (n=404) and categorized them by their post-hemorrhage use of 
anticoagulation into three groups: those who resumed anticoagulation with warfarin or 
dabigatran, and those who discontinued anticoagulation. We followed them until a clinical event 
of ischemic stroke, recurrent hemorrhage, or death through December 31, 2012. We constructed 
logistic regression models to evaluate factors impacting anticoagulation resumption, and Cox 
Proportional Hazard models to compare the risk of ischemic stroke, all-cause mortality, and 
recurrent bleeding between treatment groups. We found that CHA2DS2-Vasc and HAS-BLED 
scores did not affect the odds of post-hemorrhage anticoagulation resumption. The odds of 
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resuming anticoagulation decreased however by 11% (95%CI, 4%-18%) and 24% (95%CI, 9%-
37%) for every 5 years increase in age for warfarin and dabigatran users, respectively. 
Resumption of anticoagulation with warfarin (HR0.76; 95%CI, 0.59-0.97) or dabigatran 
(HR0.66; 95%CI 0.44-0.99) was associated with lower combined risk of ischemic stroke and all-
cause mortality than anticoagulation discontinuation. The incidence of recurrent major bleeding 
was higher for patients who were prescribed warfarin after the bleeding event than for those 
prescribed dabigatran (HR2.31; 95%CI, 1.19-4.76) or whose anticoagulation ceased (HR1.56; 
95%CI, 1.10-2.22), but did not differ between patients restarting dabigatran and those 
discontinuing anticoagulation. In conclusion, the benefit/risk ratio of dabigatran among atrial 
fibrillation patients who have survived a major hemorrhage is superior to that of warfarin and of 
anticoagulation discontinuation. 
3.2 INTRODUCTION 
Anticoagulation therapy reduces the risk of stroke associated with AF by around 60%.46 
Anticoagulation, however, is not free of risks, being an important determinant of bleeding. 
Specifically, the annual risk of major bleeding on anticoagulation has been estimated at 8-
10%.104,149,150 The optimal management of AF patients who have experienced a major bleeding 
complication is uncertain, since there are competing risks from both the resumption and the 
discontinuation of anticoagulation: while patients experiencing a major bleed are at increased 
risk of  recurrent bleeding events,63,113 they are also at a high risk of thromboembolic events, if 
anticoagulation is not reinitiated.114-117 Furthermore, there are no specific clinical guidelines to 
inform the prescription of oral anticoagulation agents after a major bleeding event.60 The 
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uncertainty surrounding decisions about the post-hemorrhage use of anticoagulation is very 
relevant from the clinical perspective, particularly because patients who are at highest risk of 
bleeding are also at highest risk of stroke.58,59,63,113   
Previous studies that examined the clinical outcomes of patients who resumed versus those 
who discontinued anticoagulation after a major bleed found that resumption of anticoagulation 
was associated with lower risk of thromboembolic events, but higher risk of bleeding.114-117 
Nevertheless, in comparing clinical outcomes between these 2 groups of patients, these studies 
did not account for the type of anticoagulation agent used.114-117 Moreover, the data used in these 
publications mostly preceded the market entry of the NOACs.114-117 Because the prescription 
patterns of the NOACs differ from those of warfarin,119 it is important to assess whether the 
patterns of post-hemorrhage resumption of anticoagulation differ between warfarin and NOAC 
users. With no requirement for routine INR monitoring, and with a lower risk of intracranial 
bleeding, the therapeutic management and bleeding profile of the NOACs are also considerably 
different from those of warfarin.92 Consequently, the clinical outcomes associated with the 
resumption of anticoagulation after a major bleeding event may differ between patients 
reinitiating warfarin therapy and those reinitiating NOACs. Therefore, it is important to 
separately evaluate the risks of stroke and recurrent bleeding among patients who resume 
anticoagulation with warfarin, those who reinitiate anticoagulation with the NOACs, and those 
who discontinue all anticoagulation.   
Our present analysis had therefore two objectives: first, to evaluate the patterns of oral 
anticoagulation use after a major bleeding event on dabigatran or warfarin and to identify 
predictors for post-hemorrhage resumption of oral anticoagulation; and second, to compare the 
combined risk of ischemic stroke and all-cause mortality and the risk of recurrent bleeding 
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events between patients who resume anticoagulation with warfarin or dabigatran versus those 
whose anticoagulation is ceased.  
3.3 METHODS  
3.3.1 Data Source and Study Population 
We obtained 2010-2012 data for a 5% random sample of Medicare beneficiaries from CMS. 
First, we identified all patients who had a diagnosis of AF151 and filled a prescription for 
dabigatran or warfarin between October 19, 2010 (date of dabigatran approval)152 and June 30, 
2012 (Figure 3-1).  
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Died during inpatient stay for bleeding 
event
(N=10, 2%)
Died during inpatient stay for bleeding 
event
(N=43, 4%)
Patients with diagnosis of AF who filled a 
prescription for dabigatran between October 19, 
2010 and June 30, 2012 (N=10,059)
Experienced a major bleeding event:      
Dabigatran Cohort 
Filled a prescription for dabigatran 
(N=117, 28%)
Filled a prescription for rivaroxaban
(N=8, 2%)
Filled a prescription for warfarin
(N=70, 17%)
Filled no prescription for oral anticoagulant
(N=217, 51%)
Patients with diagnosis of AF who filled a 
prescription for Warfarin between October 19, 2010 
and June 30, 2012 (N=79,714)
Eligible sample 
(N=22,799)
Experienced a major bleeding event:      
Warfarin Cohort 
Filled a prescription for dabigatran
(N=25, 2%)
Filled a prescription for rivaroxaban 
(N=9, 1%)
Filled a prescription for warfarin
(N=484, 41%)
Filled no prescription for oral anticoagulant 
(N=626, 53%)
Excluded: 56,915 filled a prescription for 
warfarin 6 months before October 16,2010
 
Figure 3-1: Selection of the Study Sample. 
 
To make sure that the warfarin group was representative of patients initiating warfarin and 
hence, comparable to the dabigatran group, we excluded all individuals who had filled a 
prescription for warfarin during the six months before October 19, 2010. We followed 10,059 
dabigatran users and 79,714 warfarin users from the date of the first prescription of dabigatran or 
warfarin after October 19, 2010 through December 31, 2012  until the first of the following 
events: major bleeding, discontinuation of treatment, defined as a gap in treatment for over 60 
days, 104 switch of anticoagulant, or death. Second, we selected those who experienced a major 
bleeding event that required hospitalization (index major hemorrhage) and identified those who 
were discharged alive. Third, we collected their prescriptions for oral anticoagulant agents filled 
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after the date of the index major hemorrhage and categorized them according to the oral 
anticoagulation agent used. Patients who filled a prescription for dabigatran or warfarin after the 
bleeding event were followed from the date of the first anticoagulant prescription after index 
major hemorrhage (post-hemorrhage follow-up start date) through December 31, 2012 or until 
the occurrence of a stroke, a recurrent bleeding event, or death. To set the post-hemorrhage 
follow-up start date for patients who never filled a prescription for an oral anticoagulant agent 
after the index major hemorrhage, we performed frequency matching. Frequency matching 
ensured that the time to start following patients who discontinued anticoagulation had the same 
distribution as the time to anticoagulant resumption for patients who resumed anticoagulation. 
Further details on frequency matching can be found in Appendix A. Patients who switched to 
rivaroxaban were not included in the study because of the small sample size of this treatment 
group (n=8 in the dabigatran cohort, and n=9 in the warfarin cohort). This study was approved 
by the Institutional Review Board at the University of Pittsburgh as exempt. 
3.3.2 Outcomes 
Effectiveness outcomes included ischemic stroke, all-cause mortality, and the composite of 
ischemic stroke and all-cause mortality. Ischemic stroke was defined as having one inpatient, 
emergency room or outpatient claim with primary or secondary ICD-9 codes 433, 434 or 
436.139,140 Safety outcomes included recurrent major bleeding and any recurrent bleeding event. 
A major bleeding event included any inpatient claims with primary or secondary ICD-9 codes for 
intracranial hemorrhage, hemoperitoneum, genitourinary hemorrhage, gastrointestinal 
hemorrhage, epistaxis, hemoptysis, vaginal hemorrhage, hemarthrosis, conjunctival hemorrhage 
or not otherwise specified hemorrhage (the list of ICD-9 codes is displayed in Table 3-1).104 Any 
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bleeding event included any inpatient, emergency room or outpatient claim with primary or 
secondary ICD-9 codes for the same list of bleeding events. In order to avoid double counting, 
several claims for a bleeding event were considered the same single event if they occurred within 
2 weeks of each other.153  
 
Table 3-1: International Classification of Diseases, Ninth Revision (ICD-9) Codes for Bleeding Events and for 
Corrective Surgical Procedures by Anatomical Site 
Bleeding Event 
ICD-9 Diagnosis Codes to Identify 
Bleeding Events  
ICD-9 Procedure Codes to Identify 
Corrective Procedures 
Intracranial bleeding 430, 431, 432 N/A 
Hemoperitoneum 568.81 54.12, 54.4 
Hematuria 599.7 57.49, 57.93 
GI Hemorrhage 
530.7, 531.0, 531.2, 531.4, 531.6, 532.0, 
532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 
533.6, 534.0, 534.2, 534.4, 534.6,569.3, 
535.01, 535.11, 535.21, 535.31, 535.41, 
535.51, 535.61, 535.71, 537.83, 537.84 , 
562.02 ,562.03, 562.12, 562.13, 569.85, 
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42.33, 43.41, 43.89, 44.29, 44.42, 
44.43, 44.44, 45.30, 45.34, 45.42, 
45.43, 45.73, 45.74, 45.76, 45.82, 
45.93, 46.20, 48.35, 48.36 
Epistaxis 784.7 21.01, 21.02, 21.03, 21.05, 21.31, 21.61 
Hemoptysis 786.3 30.29, 31.1, 31.69, 32.20 
Vaginal Hemorrhage 623.8, 626.2 N/A 
Hemarthrosis 719.1, 719.2 81.92 
Conjunctival hemorrhage 372.72 12.4 
NOS Hemorrhage 459 Any of the listed codes 
 
 
3.3.3 Covariates 
We evaluated how different demographic factors, clinical characteristics, anatomical location 
and severity of the index major hemorrhage affected the post-hemorrhage use of oral 
anticoagulation. All covariates were measured at the time of the index major hemorrhage. 
Demographic characteristics included age, gender, race and eligibility for Medicaid coverage. 
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Clinical covariates included CHA2DS2-Vasc score,57 HAS-BLED score,113 and number of other 
CMS priority comorbidities. Because Medicare claims data does not contain information on INR, 
we calculated the HAS-BLED score as the sum of all previous factors except labile INR.  The 
number of other CMS priority comorbidities was calculated as the sum of previous a history of 
acquired hypothyroidism, Alzheimer’s disease, related disorders or senile dementia, anemia, 
asthma, benign prostatic hyperplasia, cataract, chronic obstructive pulmonary disease, ischemic 
heart disease, hip or pelvic fracture, glaucoma, hyperlipidemia, osteoporosis, rheumatoid arthritis 
or osteoarthritis, breast cancer, colorectal cancer, prostate cancer, lung cancer and endometrial 
cancer. 
We categorized the anatomical location of the index major hemorrhage into four groups: 
intracranial bleeding, gastrointestinal hemorrhage, genitourinary hemorrhage, and other bleeding 
events, which included hemoperitoneum, epistaxis, hemoptysis, hemarthrosis, conjunctival and 
vaginal hemorrhage and not-otherwise specified hemorrhage. Measures of the severity of the 
index major hemorrhage included length of inpatient stay, intensive care unit admission, blood 
transfusion therapy, and whether the patients underwent corrective procedures in the same 
anatomical area of the bleeding. Length of inpatient stay and indicator variable for use of 
intensive care unit are variables contained in the Medicare Provider Analysis and Review 
(MedPAR) data set.154 Blood transfusion therapy was defined as having at least one procedure 
with ICD-9 procedure code 990.xx during the inpatient stay for the index major hemorrhage. To 
identify which patients underwent a corrective surgical procedure, we extracted all ICD-9 
procedure codes recorded during the inpatient stay for the index major hemorrhage, and selected 
the procedures whose objective was to correct the anatomical area where the bleeding event had 
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happened (the list of qualifying ICD-9 procedure codes for corrective surgical procedures in each 
anatomical area can be found in Table 3-1). 
3.3.4 Statistical Analysis 
We compared patient characteristics of three post-hemorrhage treatment groups in each cohort at 
the time of index major hemorrhage using chi-square tests, Fisher’s exact tests and ANOVA, as 
appropriate. To predict the probability of restarting the same anticoagulation agent used before 
the index bleeding event or switching to another agent as opposed to discontinuing oral 
anticoagulation, we constructed a multinomial logistic regression model with generalized logit 
link function, where the outcome variable was the post-hemorrhage treatment group, and 
covariates included all variables listed in the Covariates Section.  
Kaplan-Meier time-to-event curves were constructed to compare the cumulative incidence 
rates of effectiveness and safety outcomes at 3 months, 6 months and 1 year post-hemorrhage 
follow-up among the post-hemorrhage treatment groups. To further control for potential 
confounders in comparing effectiveness and safety outcomes, we constructed Cox Proportional 
Hazard models. Cox models built to compare effectiveness outcomes controlled for age, 
CHA2DS2-Vasc score, HAS-BLED score and an indicator variable for the location of the index 
major hemorrhage (1 if intracranial, 0 otherwise). Although one of the risk factors included in 
the calculation of CHA2DS2-Vasc score is age of 75 years or more, Cox models built to 
compare effectiveness outcomes controlled for continuous age for two reasons: First, age was 
unbalanced between post-hemorrhage treatment groups (Table 3-3); second; the mortality risk 
after age 75 changes markedly by every year increase in age.155 For instance, the mortality risk of 
a 85 year old patient is almost 3 times that of a 75 year old.155 Cox models built to compare 
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safety outcomes controlled for CHA2DS2-Vasc, HAS-BLED score, an indicator variable for the 
location of the index major hemorrhage (1 if intracranial, 0 otherwise), and the measures of the 
severity of the index bleeding event, as detailed above. For all time-to-event analyses, time 0 was 
the post-hemorrhage follow-up start date (defined in the Data Source and Study Population 
Section). The time at risk was censored at the end of the study period (December 31, 2012) or at 
the time of death, except for the Kaplan-Meier and Cox models whose outcome included 
mortality. In those analyses, the time at risk was only censored at the end of the study period. All 
of these analyses were performed separately for the dabigatran and the warfarin cohorts. In a 
secondary analysis, we grouped patients from the warfarin and dabigatran cohorts according to 
the treatment used after the index major hemorrhage, and compared effectiveness and safety 
outcomes using Cox models in a similar manner, as described above. All analyses were 
conducted with statistical software SAS 9.4 (Cary, NC). 
3.3.4.1 Sensitivity Analysis 
Post-hemorrhage clinical outcomes of patients who experienced an intracranial bleeding are 
likely to differ from those who bled on other anatomical locations. To examine how this may 
have affected our results for the comparative risk of post-hemorrhage clinical outcomes, we re-
run our analysis after excluding patients who experienced an intracranial bleeding. Cox models 
built to compare effectiveness outcomes controlled for age, CHA2DS2-Vasc score and HAS-
BLED score; Cox models built to compare safety outcomes controlled for CHA2DS2-Vasc score 
and HAS-BLED score. 
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3.4 RESULTS 
3.4.1 Patient Characteristics by Post-Hemorrhage Anticoagulation Use  
The proportion of patients who reinitiated anticoagulation after the index major hemorrhage was 
similar between the warfarin and dabigatran cohorts (49% for dabigatran and 47% for warfarin, 
p-value=0.497). However, dabigatran users were more likely to switch to warfarin after the 
bleeding event than warfarin users were to switch to dabigatran (17% versus 2%, p -
value<0.001). In addition, resumption of the same oral anticoagulation agent used before the 
index major hemorrhage was more common in the warfarin cohort than in the dabigatran cohort 
(41% vs. 28%, with p-value <0.001). The mortality rate during inpatient admission for the index 
major hemorrhage did not differ between the two cohorts (4% for warfarin and 2% for 
dabigatran, p-value=0.257). Details on the follow-up of each treatment group can be found in 
Table 3-2.  
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Table 3-2. Time to Post-Hemorrhage Anticoagulation Resumption, Follow-up Period, and Patterns of Post-
Hemorrhage Anticoagulation Use, by Treatment Group and Study Cohort. 
 
Treatment Used After First Major Hemorrhage 
 
Dabigatran Cohort- Mean (SD) 
Resumed 
Dabigatran 
(n=117) 
No Oral 
Anticoagulation 
(n=217) 
Switched to 
Warfarin (n=70) P-Value 
Time from first major bleeding to anticoagulation re-
start 45 (49) -- 73 (84) 0.005 
Follow-up period after first major bleeding  396 (167) 335 (201) 432 (166) <0.001 
Patterns of post-hemorrhage anticoagulation use (%)     
     Switched anticoagulation treatment 18.0 -- 1.4 <0.001 
     Discontinued anticoagulation therapy 3.4 -- 47.1 <0.001 
Warfarin Cohort- Mean (SD) 
Resumed 
Warfarin 
(n=484) 
No Oral 
Anticoagulation 
Use (n=626) 
Switched to 
Dabigatran (n=25) P-Value 
Time from first major bleeding to anticoagulation re-
start 60 (72) -- 70 (60) 0.501 
Follow-up period after first major bleeding  371 (205) 333 (205) 457 (211) <0.001 
Patterns of post-hemorrhage anticoagulation use (%)     
     Switched anticoagulation treatment 3.1 -- 8.0 0.184 
     Discontinued anticoagulation therapy 6.4 -- 28.0 <0.001 
  
Table 3-3 shows patient characteristics, anatomical location and measures of the severity of 
the index bleeding for each post-hemorrhage treatment group, by study cohort. Patients who 
experienced an intracranial bleeding, received a blood transfusion or were admitted to the 
intensive care unit were less likely to resume the anticoagulation agent used before the index 
hemorrhage. In both the warfarin and the dabigatran cohorts, older patients had a lower 
likelihood of resuming oral anticoagulation after the bleeding event. In the dabigatran cohort, 
there was no difference in CHA2DS2-Vasc and HAS-BLED scores among post-hemorrhage 
treatment groups. In the warfarin cohort, the CHA2DS2-Vasc score but not the HAS-BLED 
score was higher in patients who discontinued anticoagulation than those who reinitiated 
anticoagulation after the index bleeding event.  
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Table 3-3: Baseline Characteristics of the Cohorts, by Use of Anticoagulation after Index Major Hemorrhage 
 
Dabigatran Cohort (N=404)   Warfarin Cohort (N=1135) 
Variable - % 
Resumed 
Dabigatran 
(n=117) 
No Oral 
Anticoagulation 
(n=217) 
Switched to 
Warfarin 
(n=70) 
P-
Value   
Resumed 
Warfarin 
(n=484) 
No Oral 
Anticoagulation 
(n=626) 
Switched to 
Dabigatran 
(n=25) 
P-
Value 
Age, mean (SD) 79.64 (8.67) 81.9 (7.63) 78.73 (8.34) 0.005  77.95 (9.40) 80.20 (8.96) 76.15 (6.79) <0.001 
Male sex  35.0 31.3 32.9 0.788  45.3 39.5 52.0 0.0926 
Race    0.745     0.6568 
     White 90.6 86.6 85.7   82.6 83.2 80.0  
     Black 6.8 6.9 7.1   11.2 11.5 8.0  
     Hispanic 1.7 2.8 4.3   4.8 4.2 12.0  
     Other 0.9 3.7 2.9   1.5 1.1 0.0  
Medicaid eligibility  36.8 27.7 35.7 0.170  34.3 29.4 24.0 0.158 
CHA2DS2-Vasc score, mean (SD) 5.96 (1.77) 5.89 (1.58) 5.77 (1.99) 0.773  4.92 (1.57) 5.08 (1.60) 4.28 (1.56) 0.018 
HAS-BLED score, mean (SD) 4.16 (0.96) 4.12 (0.95) 3.94 (1.08) 0.306  4.06 (0.90) 4.12 (0.95) 4.00 (0.76) 0.478 
No. of other CMS priority comorbidities, mean (SD)  7.21 (2.53) 7.06 (2.32) 6.53 (2.80) 0.178  6.79 (2.48) 7.00 (2.40) 5.92 (2.60) 0.051 
Type of bleeding    <0.001     <0.001 
     IC 0.0 10.6 7.1   4.1 18.5 12.0  
     GI Hemorrhage 78.6 84.8 74.7   69.6 68.1 76.0  
     Genitourinary hemorrhage 4.3 2.3 2.9   8.7 2.9 4.0  
     Other 17.1 2.3 14.3   17.6 10.5 8.0  
Length of stay, median (SD) 4.0 (10.8) 4.0 (19.8) 4.0 (11.5) 0.768  4.0 (7.4) 5.0 (18.5) 4.0 (6.0) 0.253 
Use of intensive care unit 33.3 40.6 50.0 0.078  30.6 42.8 56.0 <0.001 
Transfusion 33.3 48.4 50.0 0.018  43.4 52.6 52.0 0.010 
Surgical procedures in area affected 15.4 17.5 22.9 0.427  20.5 18.4 24.0 0.575 
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3.4.2 Adjusted Odds Ratio of Post-Hemorrhage Anticoagulation Use 
Figure 3-2 shows the odds ratio of restarting dabigatran or switching to warfarin as opposed to 
discontinuing anticoagulation for patients who experienced a major bleeding event in the 
dabigatran cohort. Older patients were more likely to discontinue anticoagulation after the index 
hemorrhage. Specifically, the odds of resuming dabigatran or switching to warfarin compared to 
discontinuing anticoagulation decreased by 24% (95% CI, 9%-37%) and 28% (95% CI, 10%-
42%) for every 5 years increase in age, respectively.  
Figure 3-3 shows the odds ratio of resuming warfarin or switching to dabigatran as opposed 
to discontinuing anticoagulation after a major bleeding event in the warfarin cohort. Older 
patients, those who experienced an intracranial bleeding, were admitted to the intensive care unit, 
or received a blood transfusion were more likely to cease anticoagulation. For every 5 years 
increase in age, the odds of reinitiating warfarin compared to discontinuing anticoagulation 
decreased by 21% (95% CI, 4%-18%). The odds of resuming warfarin were 79% (95% CI, 66%-
88%) lower for patients who experienced an intracranial hemorrhage compared to those who 
experienced a gastrointestinal bleeding, and 31% (95% CI, 11%-47%) lower for patients 
receiving a blood transfusion than for those who did not. 
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Resume DabigatranNo Anticoagulant Use No Anticoagulant Use Switch to Warfarin
0.2 2 0.2 2
Odds Ratio Resume Dabigatran vs No Anticoagulant Use                            
(95% Confidence Interval)
Odds Ratio Switch to Warfarin vs No Anticoagulant Use                            
(95% Confidence Interval)
Age, per 5 years 0.76 (0.63-0.91) 0.72 (0.58-0.90)
Male sex 1.08 (0.60-1.95) 1.09 (0.54-2.19)
Race
Black vs white 0.73 (0.26-2.08) 0.61 (0.19-1.95)
Hispanic vs white 0.68 (0.12-3.74) 1.74 (0.39-7.81)
Other race vs white 0.10 (0.01-1.00) 0.39 (0.06-2.34)
Medicaid eligible 1.48 (0.84-2.60) 1.69 (0.88-3.25)
CHA2DS2-Vasc score 1.10 (0.87-1.37) 1.21 (0.93-1.57)
HAS-BLED score - labile INR 1.12 (0.79-1.58) 0.79 (0.52-1.19)
No. of other CMS priority comorbidities 1.03 (0.92-1.16) 0.94 (0.82-1.08)
Type of bleeding
IC vs GI -- 0.61 (0.19-1.95)
Hematuria vs GI 1.76 (0.44-6.99) 1.74 (0.39-7.81)
Other vs GI 8.90 (2.88-27.53) 0.39 (0.06-2.34)
Length of stay, per 5 days 0.97 (0.89-1.05) 1.69 (0.88-3.25)
Use of intensive care unit 0.98 (0.58-1.65) 1.21 (0.93-1.57)
Trasfusion 0.61 (0.36-1.02) 0.79 (0.52-1.19)
Corrective surgical procedure 0.90 (0.47-1.73) 0.94 (0.82-1.08)
 
Figure 3-2: Odds Ratio of Post-Hemorrhage Anticoagulation Use for the Dabigatran Cohort 
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Resume WarfarinNo Anticoagulant Use No Anticoagulant Use Switch to Dabigatran
Odds Ratio Resume Warfarin vs No Anticoagulant Use                            
(95% Confidence Interval)
Odds Ratio Switch to Dabigatran vs No Anticoagulant Use                            
(95% Confidence Interval)
Age, per 5 years 0.89 (0.82-0.96) 0.87 (0.68-1.13)
Male sex 1.13 (0.84-1.50) 0.87 (0.34-2.20)
Race
Black vs white 0.83 (0.54-1.26) 0.66 (0.14-3.15)
Hispanic vs white 1.12 (0.59-2.12) 3.50 (0.86-14.30)
Other race vs white 1.45 (0.47-4.46) --
Medicaid eligible 1.27 (0.95-1.69) 0.68 (0.24-1.95)
CHA2DS2-Vasc score 1.00 (0.89-1.13) 0.71 (0.49-1.05)
HAS-BLED score - labile INR 0.97 (0.81-1.17) 1.39 (0.78-2.47)
No. of other CMS priority comorbidities 0.99 (0.93-1.05) 0.92 (0.75-1.12)
Type of bleeding
IC vs GI 0.21 (0.12-0.34) 0.45 (0.12-1.71)
Hematuria vs GI 2.38 (1.32-4.32) 1.11 (0.13-9.43)
Other vs GI 1.39 (0.96-2.01) 0.62 (0.13-2.86)
Length of stay, per 5 days 0.94 (0.86-1.03) 0.89 (0.58-1.35)
Use of intensive care unit 0.72 (0.55-0.94) 1.73 (0.74-4.05)
Trasfusion 0.69 (0.53-0.89) 0.83 (0.36-1.93)
Corrective surgical procedure 1.05 (0.76-1.44) 1.17 (0.43-3.13)
0.2 2 0.2 2
 
Figure 3-3: Odds Ratio of Post-Hemorrhage Anticoagulation Use for the Warfarin Cohort. 
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3.4.3 Stroke and All-Cause Mortality 
Table 3-4 shows the number of events and the unadjusted cumulative incidence rates of clinical 
outcomes by post-hemorrhage treatment group. Before adjustment, there was no difference in the 
composite risk of stroke and all-cause mortality among treatment groups in the dabigatran 
cohort. However, dabigatran users who resumed dabigatran after the index bleeding had lower 
mortality risk (cumulative incidence of death at 3 months 0.01; 95% CI, 0.00-0.03) than those 
who ceased anticoagulation therapy (0.12; 95% CI, 0.07-0.16). In the warfarin cohort, the risk of 
mortality and the composite risk of stroke and all-cause mortality were lower among patients 
who restarted warfarin compared to those who did not reinitiate anticoagulation.  
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Table 3-4: Number of Events and Unadjusted Cumulative Incidence Rates of Post-Hemorrhage Clinical 
Outcomes, by Cohort and Post-Hemorrhage Treatment Group 
 
Dabigatran Cohort 
Resumed Dabigatran 
(n=117) 
No Oral 
Anticoagulation 
(n=217) 
Switched to Warfarin 
(n=70) 
Effectiveness Outcomes    
 
Ischemic Stroke and All-Cause 
Mortality     
      Number of events (%) 21 (18.0) 48 (22.1) 13 (18.6) 
      Cumulative incidence (95% CI)    
           At 3 months 0.07 ( 0.02 , 0.12 ) 0.18 ( 0.13 , 0.24 ) 0.13 ( 0.05 , 0.21 ) 
           At 6 months 0.13 ( 0.07 , 0.19 ) 0.21 ( 0.15 , 0.27 ) 0.15 ( 0.06 , 0.23 ) 
           At 1 yr 0.21 ( 0.13 , 0.29 ) 0.26 ( 0.19 , 0.33 ) 0.22 ( 0.11 , 0.33 ) 
 Ischemic Stroke     
      Number of events (%) 20 (17.1) 23 (10.6) 12 (17.1) 
      Cumulative incidence (95% CI)    
           At 3 months 0.06 ( 0.02 , 0.11 ) 0.07 ( 0.03 , 0.11 ) 0.12 ( 0.04 , 0.20 ) 
           At 6 months 0.12 ( 0.06 , 0.18 ) 0.08 ( 0.04 , 0.13 ) 0.13 ( 0.05 , 0.22 ) 
           At 1 yr 0.20 ( 0.12 , 0.29 ) 0.15 ( 0.08 , 0.21 ) 0.21 ( 0.10 , 0.32 ) 
 All-Cause Mortality    
      Number of events (%) 2 (1.7) 25 (11.5) 2 (2.9) 
      Cumulative incidence (95% CI)    
           At 3 months 0.01 ( 0.00 , 0.03 ) 0.12 ( 0.07 , 0.16 ) 0.03 ( 0.00 , 0.07 ) 
           At 6 months 0.02 ( 0.00 , 0.04 ) 0.13 ( 0.08 , 0.18 ) 0.03 ( 0.00 , 0.07 ) 
           At 1 yr 0.02 ( 0.00 , 0.04 ) 0.13 ( 0.08 , 0.18 ) 0.03 ( 0.00 , 0.07 ) 
Safety Outcomes    
 Major Recurrent Hemorrhage    
      Number of events (%) 8 (6.8) 13 (6.0) 6 (8.6) 
      Cumulative incidence (95% CI)    
           At 3 months 0.04 ( 0.00 , 0.07 ) 0.05 ( 0.02 , 0.08 ) 0.06 ( 0.00 , 0.11 ) 
           At 6 months 0.06 ( 0.01 , 0.10 ) 0.05 ( 0.02 , 0.09 ) 0.06 ( 0.00 , 0.11 ) 
           At 1 yr 0.07 ( 0.02 , 0.11 ) 0.09 ( 0.04 , 0.14 ) 0.09 ( 0.01 , 0.17 ) 
 Any Recurrent Hemorrhage    
      Number of events (%) 40 (34.2) 60 (27.7) 26 (37.1) 
      Cumulative incidence (95% CI)    
           At 3 months 0.24 ( 0.16 , 0.32 ) 0.24 ( 0.18 , 0.30 ) 0.26 ( 0.16 , 0.36 ) 
           At 6 months 0.29 ( 0.21 , 0.37 ) 0.31 ( 0.24 , 0.38 ) 0.29 ( 0.18 , 0.40 ) 
            At 1 yr 0.34 ( 0.25 , 0.44 ) 0.40 ( 0.31 , 0.49 ) 0.38 ( 0.25 , 0.51 ) 
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Table 3-4 continued 
Warfarin Cohort Resumed Warfarin (n=484) 
No Oral 
Anticoagulation 
(n=626) 
Switched to 
Dabigatran (n=25) 
Effectiveness Outcomes    
 
Ischemic Stroke and All-Cause 
Mortality     
      Number of events (%) 92 (19.0) 144 (23.0) 6 (24.0) 
      Cumulative incidence (95% CI)    
           At 3 months 0.10 ( 0.07 , 0.13 ) 0.20 ( 0.17 , 0.23 ) 0.18 ( 0.02 , 0.33 ) 
           At 6 months 0.16 ( 0.12 , 0.19 ) 0.23 ( 0.20 , 0.27 ) 0.23 ( 0.05 , 0.40 ) 
           At 1 yr 0.23 ( 0.18 , 0.27 ) 0.26 ( 0.23 , 0.30 ) 0.28 ( 0.09 , 0.48 ) 
 Ischemic Stroke     
      Number of events (%) 66 (13.6) 67 (10.7) 5 (20.0) 
      Cumulative incidence (95% CI)    
           At 3 months 0.06 ( 0.04 , 0.09 ) 0.09 ( 0.06 , 0.11 ) 0.14 (0.00 , 0.28 ) 
           At 6 months 0.11 ( 0.07 , 0.14 ) 0.11 ( 0.08 , 0.14 ) 0.19 ( 0.02 , 0.36 ) 
           At 1 yr 0.17 ( 0.13 , 0.21 ) 0.14 ( 0.11 , 0.18 ) 0.25 ( 0.06 , 0.44 ) 
 All-Cause Mortality    
      Number of events (%) 27 (5.6) 86 (13.7) 1 (4.0) 
      Cumulative incidence (95% CI)    
           At 3 months 0.03 ( 0.02 , 0.05 ) 0.14 ( 0.11 , 0.17 ) 0.04 ( 0.00 , 0.13 ) 
           At 6 months 0.06 ( 0.03 , 0.08 ) 0.15 ( 0.12 , 0.18 ) 0.04 ( 0.00 , 0.13 ) 
           At 1 yr 0.07 ( 0.04 , 0.09 ) 0.15 ( 0.12 , 0.18 ) 0.04 ( 0.00 , 0.13 ) 
Safety Outcomes    
 Major Recurrent Hemorrhage    
      Number of events (%) 68 (14.1) 44 (7.0) 1 (4.0) 
      Cumulative incidence (95% CI)    
           At 3 months 0.08 ( 0.06 , 0.11 ) 0.06 ( 0.04 , 0.08 ) 0.00 ( 0.00 , 0.00 ) 
           At 6 months 0.11 ( 0.08 , 0.14 ) 0.08 ( 0.06 , 0.11 ) 0.00 ( 0.00 , 0.00 ) 
           At 1 yr 0.17 ( 0.13 , 0.21 ) 0.10 ( 0.07 , 0.13 ) 0.00 ( 0.00 , 0.00 ) 
 Any Recurrent Hemorrhage    
      Number of events (%) 170 (35.1) 188 (30.0) 5 (20.0) 
      Cumulative incidence (95% CI)    
           At 3 months 0.26 ( 0.22 , 0.30 ) 0.29 ( 0.25 , 0.33 ) 0.17 ( 0.02 , 0.33 ) 
           At 6 months 0.33 ( 0.29 , 0.38 ) 0.35 ( 0.30 , 0.39 ) 0.17 ( 0.02 , 0.33 ) 
            At 1 yr 0.42 ( 0.37 , 0.47 ) 0.39 ( 0.34 , 0.43 ) 0.17 ( 0.02 , 0.33 ) 
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Figure 3-4 shows the hazard ratios of effectiveness outcomes after adjustment for potential 
confounders. Here again, in the dabigatran cohort, the risk of all-cause mortality was lower for 
patients who resumed dabigatran (HR 0.13; 95% CI, 0.03-0.58) or switched to warfarin (HR 
0.21; 95% CI, 0.05-0.91) than for those who did not reinitiate anticoagulation. The composite 
risk of ischemic stroke and all-cause mortality was however similar among post-hemorrhage 
treatment groups in the dabigatran cohort. In the warfarin cohort, resumption of warfarin was 
associated with lower composite risk of ischemic stroke and all-cause mortality (HR 0.75; 95% 
CI, 0.57-0.98) and lower risk of all-cause mortality (HR 0.37; 95% CI, 0.23-0.58) than 
discontinuation of anticoagulation. In both the warfarin and the dabigatran cohorts, the risk of 
ischemic stroke did not significantly differ among post-hemorrhage treatment groups. 
When the two cohorts were analyzed simultaneously based on the treatment received after 
the index hemorrhage, we found that the composite risk of ischemic stroke and all-cause 
mortality was lower for patients who were prescribed warfarin (HR 0.76; 95% CI, 0.59-0.97) or 
dabigatran (HR 0.66; 95% CI, 0.44-0.99) than for those whose anticoagulation was discontinued 
after the major bleeding event. Furthermore, resumption of anticoagulation with warfarin (HR 
0.35; 95% CI, 0.23-0.53) or with dabigatran (HR 0.13; 95% CI, 0.04-0.41) was associated with 
decreased mortality, compared to discontinuation of anticoagulation. Once again, there was no 
difference in the risk of ischemic stroke among post-hemorrhage treatment groups. 
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Ischemic Stroke/All-Cause Mortality 0.67 (0.40-1.15) 0.70 (0.38-1.31) 1.04 (0.52-2.09)
     All-Cause Mortality 0.13 (0.03-0.58) 0.21 (0.05-0.91) 1.57 (0.22-11.18)
     Ischemic Stroke 1.29 (0.69-2.43) 1.29 (0.63-2.65) 1.00 (0.48-2.09)
Major Recurrent Hemorrhage 0.68 (0.27-1.72) 1.08 (0.41-2.88) 1.47 (0.58-3.72)
Any Recurrent Hemorrhage 0.87 (0.58-1.32) 1.04 (0.65-1.66) 1.20 (0.70-2.00)
Ischemic Stroke/All-Cause Mortality 0.75 (0.57-0.98) 0.96 (0.42-2.19) 1.28 (0.56-2.94)
     All-Cause Mortality 0.35 (0.23-0.55) 0.27 (0.04-1.95) 0.77 (0.11-5.69)
     Ischemic Stroke 1.26 (0.88-1.80) 1.81 (0.72-4.53) 1.43 (0.57-3.58)
Major Recurrent Hemorrhage 1.60 (1.09-2.36) 0.38 (0.05-2.79) 0.24 (0.03-1.73)
Any Recurrent Hemorrhage 0.95 (0.77-1.18) 0.42 (0.17-1.02) 0.44 (0.18-1.08)
Ischemic Stroke/All-Cause Mortality 0.76 (0.59-0.97) 0.66 (0.44-0.99) 0.87 (0.57-1.33)
     All-Cause Mortality 0.35 (0.23-0.53) 0.13 (0.04-0.41) 0.37 (0.11-1.22)
     Ischemic Stroke 1.27 (0.93-1.75) 1.37 (0.86-2.17) 1.07 (0.68-1.69)
Major Recurrent Hemorrhage 1.56 (1.10-2.22) 0.65 (0.32-1.33) 0.42 (0.21-0.84)
Any Recurrent Hemorrhage 0.97 (0.80-1.17) 0.77 (0.56-1.07) 0.80 (0.58-1.10)
Two cohorts combined
Switched to Warfarin vs Resumed Dabigatran 
Effectiveness Outcomes
Safety Outcomes
Dabigatran cohort
Warfarin cohort
Effectiveness Outcomes
Safety Outcomes
Adjusted Hazard Ratio (% CI)
Warfarin vs No Oral Anticoagulant Use Dabigatran vs No Oral Anticoagulant Use Dabigatran vs Warfarin
Resumed Warfarin vs No Oral Anticoagulant 
Use
Swtiched to Dabigatran vs No Oral 
Anticoagulant Use Switched to Dabigatran vs Resumed Warfarin 
Effectiveness Outcomes
Safety Outcomes
Resumed Dabigatran vs No Oral 
Anticoagulant Use  
Switched to Warfarin vs No Oral 
Anticoagulant Use
 
Figure 3-4: Adjusted Hazard Ratios of Post-Hemorrhage Clinical Outcomes 
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3.4.4 Recurrent Bleeding  
There were no differences in the unadjusted risk of bleeding events among post-hemorrhage 
treatment groups in the dabigatran cohort (Table 3-4). However, in the warfarin cohort, the 
unadjusted risk of recurrent major bleeding was lower for patients who discontinued 
anticoagulation (cumulative incidence at 1 year 0.10; 95% CI, 0.07-0.13) than for those who 
restarted warfarin after the index hemorrhage (0.17; 95% CI, 0.13-0.21). 
These unadjusted results were consistent with the findings of the adjusted analysis. The 
risks of major and any bleeding events were similar for 3 treatment groups in the dabigatran 
cohort (Figure 3-4). In the warfarin cohort, however, the risk of major bleeding was higher for 
patients resuming warfarin compared to those discontinuing all anticoagulation (HR 1.60; 95% 
CI, 1.09-2.36).   
When the two cohorts were combined based on the treatment received after the index 
hemorrhage, we found that the risk of major hemorrhage was higher for patients who were 
prescribed warfarin than for those who were prescribed dabigatran or who discontinued 
anticoagulation therapy. Specifically, the hazard ratio of recurrent major bleeding was 0.42 (95% 
CI, 0.21-0.84) for dabigatran compared to warfarin, and 1.59 (95% CI, 1.10-2.22) for warfarin 
compared to anticoagulation discontinuation. The risk of bleeding did not differ between patients 
who were prescribed dabigatran after the index hemorrhage and those whose anticoagulation was 
discontinued (HR 0.66; 95% CI, 0.32-1.33). 
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3.4.5 Sensitivity Analyses 
Our results for the hazard ratios of post-hemorrhage clinical outcomes were robust to the 
exclusion of patients who experienced an intracranial bleeding event (Table 3-5). 
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Table 3-5. Results of Sensitivity Analyses. 
Sensitivity Analysis Base Case Sensitivity Analysis Base Case Sensitivity Analysis Base Case
Ischemic Stroke/All-Cause Mortality 0.64 (0.38-1.10) 0.67 (0.40-1.15) 0.57 (0.28-1.14) 0.70 (0.38-1.31) 0.88 (0.42-1.88) 1.04 (0.52-2.09)
     All-Cause Mortality 0.13 (0.03-0.56) 0.13 (0.03-0.58) 0.11 (0.01-0.82) 0.21 (0.05-0.91) 0.83 (0.08-9.20) 1.57 (0.22-11.18)
     Ischemic Stroke 1.24 (0.65-2.34) 1.29 (0.69-2.43) 1.17 (0.54-2.54) 1.29 (0.63-2.65) 0.95 (0.44-2.03) 1.00 (0.48-2.09)
Major Recurrent Hemorrhage 0.71 (0.28-1.83) 0.68 (0.27-1.72) 1.20 (0.44-3.30) 1.08 (0.41-2.88) 1.69 (0.57-5.00) 1.47 (0.58-3.72)
Any Recurrent Hemorrhage 0.91 (0.60-1.39) 0.87 (0.58-1.32) 1.23 (0.76-1.98) 1.04 (0.65-1.66) 1.34 (0.81-2.24) 1.20 (0.70-2.00)
Sensitivity Analysis Base Case Sensitivity Analysis Base Case Sensitivity Analysis Base Case
Ischemic Stroke/All-Cause Mortality 0.71 (0.54-0.95) 0.75 (0.57-0.98) 0.72 (0.26-1.95) 0.96 (0.42-2.19) 1.00 (0.37-2.74) 1.28 (0.56-2.94)
     All-Cause Mortality 0.35 (0.22-0.55) 0.35 (0.23-0.55) 0.29 (0.04-2.12) 0.27 (0.04-1.95) 0.84 (0.11-6.23) 0.77 (0.11-5.69)
     Ischemic Stroke 1.25 (0.84-1.86) 1.26 (0.88-1.80) 1.31 (0.41-4.26) 1.81 (0.72-4.53) 1.05 (0.33-3.37) 1.43 (0.57-3.58)
Major Recurrent Hemorrhage 1.63 (1.09-2.44) 1.60 (1.09-2.36) 0.42 (0.06-3.06) 0.38 (0.05-2.79) 0.26 (0.04-1.85) 0.24 (0.03-1.73)
Any Recurrent Hemorrhage 0.94 (0.75-1.18) 0.95 (0.77-1.18) 0.50 (0.20-1.21) 0.42 (0.17-1.02) 0.53 (0.22-1.28) 0.44 (0.18-1.08)
Sensitivity Analysis Base Case Sensitivity Analysis Base Case Sensitivity Analysis Base Case
Ischemic Stroke/All-Cause Mortality 0.71 (0.55-0.92) 0.76 (0.59-0.97) 0.60 (0.39-0.93) 0.66 (0.44-0.99) 0.85 (0.55-1.33) 0.87 (0.57-1.33)
     All-Cause Mortality 0.33 (0.22-0.51) 0.35 (0.23-0.53) 0.13 (0.04-0.41) 0.13 (0.04-0.41) 0.39 (0.12-1.29) 0.37 (0.11-1.22)
     Ischemic Stroke 1.24 (0.76-2.02) 1.27 (0.93-1.75) 1.24 (0.88-1.76) 1.37 (0.86-2.17) 1.00 (0.62-1.61) 1.07 (0.68-1.69)
Major Recurrent Hemorrhage 1.61 (1.12-2.32) 1.56 (1.10-2.22) 0.68 (0.33-1.39) 0.65 (0.32-1.33) 0.42 (0.21-0.85) 0.42 (0.21-0.84)
Any Recurrent Hemorrhage 0.99 (0.81-1.21) 0.97 (0.80-1.17) 0.80 (0.58-1.11) 0.77 (0.56-1.07) 0.80 (0.58-1.12) 0.80 (0.58-1.10)
Effectiveness Outcomes
Adjusted Hazard Ratio (% CI)
Dabigatran cohort
Effectiveness Outcomes
Safety Outcomes
Warfarin cohort
Dabigatran vs Warfarin
Switched to Dabigatran vs Resumed Warfarin 
Switched to Warfarin vs Resumed Dabigatran Resumed Dabigatran vs No Oral 
Anticoagulant Use  
Warfarin vs No Oral Anticoagulant Use
Resumed Warfarin vs No Oral Anticoagulant 
Use
Dabigatran vs No Oral Anticoagulant Use
Swtiched to Dabigatran vs No Oral Anticoagulant 
Use
Switched to Warfarin vs No Oral Anticoagulant 
Use
Safety Outcomes
Two cohorts combined
Effectiveness Outcomes
Safety Outcomes
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3.5 DISCUSSION 
To the best of our knowledge, our study is the first real-world analysis comparing clinical 
outcomes after a major hemorrhage among patients who reinitiated anticoagulation therapy with 
dabigatran or warfarin, and those who never resumed anticoagulation. Our study has four main 
findings: First, we found that post-hemorrhage use of warfarin was more common than that of 
dabigatran. Second, we observed that the CHA2DS2-Vasc and HAS-BLED scores did not 
impact the likelihood of reinitiating anticoagulation after a major bleeding event. In contrast, age, 
anatomical location and severity of the index bleeding event were the most important 
determinants of resuming anticoagulation. Third, compared to discontinuation of all 
anticoagulation, resumption of anticoagulation therapy with either dabigatran or warfarin was 
associated with higher rates of survival and stroke-free survival. Fourth, the risk of recurrent 
major hemorrhage was higher for patients who were prescribed warfarin after a first major 
bleeding compared to those who were prescribed dabigatran or those whose anticoagulation was 
never reinitiated.   
Using a US nationally representative sample, we found that 51% of warfarin users and 53% 
of dabigatran users did not reinitiate anticoagulation after a first major bleeding event. This 
finding replicates the result from Qureshi et al., who analyzed data from a health system in 
Michigan and found that 51% of AF patients who experienced a major gastrointestinal bleeding 
while using warfarin interrupted warfarin therapy after the bleeding event.114 When assessing the 
determinants of post-hemorrhage anticoagulation resumption, we observed that CHA2DS2-Vasc 
and HAS-BLED scores did not impact the likelihood of anticoagulation resumption. This 
surprising finding is in agreement with a recent study by Staerk and colleagues, who used data 
from a cohort of Danish patients with AF, finding that CHA2DS2-Vasc and HAS-BLED scores 
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did not differ between patients who resumed and those who never reinitiated anticoagulation 
after a major gastrointestinal hemorrhage.115 In such study, Staerk et al. found that the 
resumption of anticoagulation was associated with increased risk of recurrent gastrointestinal 
hemorrhage, which conflicts with the results from Qureshi and colleagues, who found no 
differences in the risk of recurrent bleeding between those who reinitiated and those who never 
resumed anticoagulation.114,115 Our analysis, which included patients experiencing major 
bleeding events in different anatomical locations, demonstrated that the resumption of warfarin 
therapy but not of dabigatran was associated with higher risk of major bleeding than the 
discontinuation of anticoagulation.  
When comparing effectiveness outcomes among post-hemorrhage treatment groups, we 
found that the resumption of anticoagulation after a major hemorrhage was associated with 
increased survival, as compared to discontinuation of anticoagulation, which is consistent with 
previous studies.114,115,117 Our estimate for the hazard ratio of all-cause mortality for patients who 
reinitiated warfarin compared to those who discontinued anticoagulation (HR 0.35; 95% CI,0.23-
0.54) is particularly similar to the one reported by Staerk and collaborators (HR 0.39; 95% CI, 
0.34-0.46).115 Regardless of the consistency of these findings, the association of anticoagulation 
resumption with increased survival may be subject to residual confounding, because patients 
who discontinued anticoagulation had higher burden of disease than those who resumed 
anticoagulation. Our Cox Proportional Hazard models built to compare the risk of all-cause 
mortality between post-hemorrhage treatment groups controlled for CHA2DS2-vasc and HAS-
BLED scores; however, these prediction tools do not distinguish the severity of the risk factors 
included in their calculation. For instance, the creatinine clearance of patients with chronic 
kidney disease or the ejection fraction of patients with heart failure may have been lower among 
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subjects whose anticoagulation was discontinued than those who were prescribed warfarin or 
dabigatran after the bleeding event. Furthermore, conditions other than the ones included in the 
calculation of CHA2DS2-Vasc and HAS-BLED scores may have been unbalanced between 
patients who restarted anticoagulation and those who did not. Consequently, our results for the 
comparative risk of all-cause mortality between patients who reinitiated and those who 
discontinued anticoagulation should be interpreted with caution.  
Our study contributes significantly to the existing literature because, as opposed to previous 
work, it stratifies treatment groups into two cohorts according to the type of anticoagulation 
agent used after the index bleeding event. In doing so, we demonstrate the benefit of the use of 
anticoagulation therapy after a major bleeding event. More specifically, we show that patients 
who use dabigatran after a bleeding event have a lower incidence of stroke and all-cause 
mortality but similar risk of bleeding than those who discontinue anticoagulation. Furthermore, 
we find that the benefit/risk ratio of post-hemorrhage dabigatran use is superior to that of 
warfarin because, with comparable effectiveness, dabigatran is associated with lower rates of 
recurrent bleeding. In contrast, we observe that only half of the patients who experience a major 
bleeding event restart anticoagulation therapy and that among those who do, the use of 
dabigatran is substantially less common than the use of warfarin. The lower tendency to 
prescribe dabigatran as compared to warfarin after a major hemorrhage may be explained by two 
reasons. First, whereas warfarin therapy requires routine INR monitoring, laboratory coagulation 
markers are not routinely monitored for patients on dabigatran. In this context, clinicians may be 
under the impression that they have more control over the coagulation status of patients on 
warfarin than those on dabigatran, particularly in the early aftermath of a major bleeding event. 
Second, clinicians may have been especially risk-averse to prescribe dabigatran because of the 
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warnings on the risk of severe bleeding with dabigatran released by the main international 
regulatory agencies throughout 2011,156,157 as well as the lack of antidote to reverse the 
anticoagulation effects of dabigatran in the time period that this study captures. In this scenario, 
patients who were prescribed dabigatran after the index hemorrhage were likely to be those at 
lowest risk of recurrent bleeding.  These risk-averse prescription patterns of dabigatran may have 
introduced residual confounding in our results for the comparative risk of bleeding events with 
warfarin and dabigatran. With the approval in October 2015 of idarucizumab, a dabigatran-
binding monoclonal antibody fragment, prescribers may become more comfortable using 
dabigatran in patients who have already suffered a major bleeding event on anticoagulation.77 
Therefore, it will be important to repeat analyses similar to ours as newer Medicare Part D data 
that represents the period after the approval of idarucizumab become available. 
In addition to the fact that our results reflect the early experience with dabigatran, our study 
is subject to three main limitations. First, claims data do not contain laboratory results and 
therefore, we did not have information about the INR levels of our study subjects, which may 
have affected the decision to restart anticoagulation therapy in patients who bled on warfarin. 
Second, we did not stratify our analyses by the anatomical location of the index bleeding event. 
The post-hemorrhage clinical outcomes of patients experiencing an intracranial bleeding, for 
example, are likely to be different from those who presented with a gastrointestinal bleeding. We 
did however control for the anatomical location of the index major hemorrhage when comparing 
effectiveness and safety outcomes among treatment groups, which should mitigate this problem. 
Third, in our comparison of clinical outcomes between treatment groups, we did not stratify by 
the dose of dabigatran used. Nevertheless, the use of dabigatran 75mg was relatively uncommon 
in the period that our study represents—less than 10% of Medicare beneficiaries with AF on 
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dabigatran were prescribed dabigatran 75 mg in the first two years after dabigatran approval,105 
and previous cohort studies comparing the risk of bleeding with dabigatran and warfarin have 
shown that grouping of two doses of dabigatran did not alter the findings.104-106 With dabigatran 
110mg gaining FDA approval in November 2015,96 it will be informative to reanalyze 2016-
2017 Medicare claims data and compare the effectiveness and safety outcomes of patients who 
discontinue oral anticoagulation, as opposed to those who are started on dabigatran 150mg, 
dabigatran 110mg, dabigatran 75mg, or warfarin.  
In conclusion, we demonstrate that the resumption of anticoagulation with either dabigatran 
or warfarin after a major bleeding event is associated with increased survival and stroke-free 
survival, compared to discontinuing anticoagulation. In addition, we show that the risk of 
recurrent hemorrhage is higher with warfarin than dabigatran. Our findings suggest that the 
benefit/risk ratio of dabigatran in the prevention of stroke among AF patients who have survived 
a major hemorrhage is superior to that of warfarin therapy or anticoagulation discontinuation, but 
will need to be validated in other patient cohorts and with more recent data. 
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4.0  COST-EFFECTIVENESS OF NON-VITAMIN K ANTAGONIST ORAL 
ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL 
FIBRILLATION AT HIGH RISK OF BLEEDING  
4.1 ABSTRACT 
There is conflicting evidence on the comparative cost-effectiveness of apixaban 5mg and 
dabigatran 150mg, and the cost-effectiveness of edoxaban 60mg has never been evaluated from 
the US perspective. The objective of this manuscript was to compare the cost-effectiveness of 
edoxaban 60mg, apixaban 5mg, dabigatran 150mg, dabigatran 110mg, rivaroxaban 20mg and 
dose-adjusted warfarin in the prevention of stroke and systemic embolism among 65 year old 
atrial fibrillation patients who are at high-risk of bleeding, which was defined as having a HAS-
BLED score greater than or equal to 3.Our baseline cohort simulated patients at high risk of 
bleeding because first, around 40% of Medicare beneficiaries on oral anticoagulation have HAS-
BLED scores equal to or greater than 3, and second, patients at high risk of bleeding are usually 
at high risk of stroke too, since risk factors for bleeding events also increase the thromboembolic 
risk. We constructed a Markov state-transition model to evaluate lifetime costs and quality-
adjusted life years (QALYs) with each of the six anticoagulation treatments from the perspective 
of US third-party payers. During each Markov cycle, patients could experience a severe stroke, 
other thromboembolic event including minor ischemic stroke, transient ischemic attack and 
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systemic embolism, an intracranial bleeding or an extracranial bleeding event. Probabilities of 
clinical events were obtained from the RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-
TIMI clinical trials; costs were derived from the Healthcare Cost and Utilization Project, and 
other published studies. To select cost-effective alternatives, we used a $100,000 per QALY 
gained willingness-to-pay threshold. Because edoxaban is only indicated in patients with 
creatinine clearance lower than 95ml/min, we re-run our analyses after excluding edoxaban from 
the compared strategies. We found that treatment with edoxaban 60mg cost $77,565 per QALY 
gained compared to warfarin, and apixaban 5mg cost $108,631/QALY gained compared to 
edoxaban 60mg. When edoxaban was not included in the analysis, treatment with apixaban 5mg 
would cost $84,128 per QALY gained, compared to warfarin. Dabigatran 150mg, dabigatran 
110mg and rivaroxaban 20mg were dominated strategies. Results were most sensitive to non-
vitamin K antagonist oral anticoagulant costs, and the relative risks of thromboembolic and 
bleeding events with apixaban 5mg and edoxaban 60mg. In conclusion, for patients with 
creatinine clearance lower than 95ml/min, edoxaban 60mg was the most cost-effective oral 
anticoagulation treatment. Apixaban 5mg, however, was the most effective strategy and it would 
be cost-effective for this population if its price was reduced 1.3%, or if a somewhat higher cost-
effectiveness criterion of $150,000/QALY gained or more was used. For patients with creatinine 
clearance higher than 95ml/min, for whom edoxaban is not indicated, apixaban 5mg was the 
most cost-effective oral anticoagulation treatment. 
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4.2 INTRODUCTION 
AF is the most prevalent type of arrhythmia and a leading cause of stroke158,159 – it is associated 
with a 5-fold increase in the risk of stroke, and around 15% of strokes in all age groups and 24% 
in elderly patients can be attributed to AF.160,161 The use of oral anticoagulation therapy has been 
found to reduce stroke risk by around 60%;46 however, anticoagulation is associated with an 
increased risk of bleeding. For this reason, clinical guidelines recommend the assessment of the 
risk of stroke, as measured by the CHA2DS2-Vasc score, before the prescription of oral 
anticoagulation.60,162 In patients with CHA2DS2-Vasc scores lower than 2, the risk of bleeding 
can outweigh the benefits of stroke risk reduction;53 however, there is solid evidence supporting 
the use of anticoagulation in patients with CHA2DS2-Vasc scores equal to or greater than 2, 
regardless of the risk of bleeding.46,51,52 The risk of bleeding is measured by the HAS-BLED 
score; HAS-BLED scores equal to or greater than 3 indicate high risk of bleeding.113 
Representing around 40% of Medicare beneficiaries on oral anticoagulation,135 patients with 
HAS-BLED scores equal to or greater than 3 are usually at high risk of stroke too, because risk 
factors for bleeding events also increase the thromboembolic risk.58,59,113 For this reason, the 
appropriate management of anticoagulation therapy in this subgroup of AF patients is especially 
relevant.  
Before 2010, warfarin was the only oral anticoagulant approved for the prevention of 
stroke and systemic embolism in AF. In October 2010, dabigatran was the first NOAC to reach 
market entry.96 The approval of dabigatran was based on the results from the RE-LY trial, which 
showed that dabigatran 150mg was superior to warfarin in the prevention of stroke and systemic 
embolism, but similar in the risk of bleeding.88 The RE-LY trial also evaluated dabigatran 
110mg,88 an intermediate strength that was approved by the main international regulatory 
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agencies except for the FDA for stroke prevention in patients with high risk of bleeding.93-95 
Since the approval of dabigatran in 2010, three new agents have gained the FDA approval for the 
prevention of stroke among AF patients with normal kidney function: rivaroxaban 20 mg in 
November 2011, apixaban 5mg in December 2012 and edoxaban 60mg in January 2015.88-91 
NOACs present certain advantages over traditional anticoagulation therapy with warfarin, 
such as fewer interactions and no requirement for routine monitoring of laboratory coagulation 
markers; however, NOACs are around 15 times more costly than warfarin.88-91 As a result, 
NOACs have garnered special attention regarding their cost-effectiveness. Specifically, three 
studies have simultaneously compared the cost-effectiveness of apixaban 5mg, rivaroxaban 
20mg, dabigatran 150mg and warfarin from the US perspective, finding conflicting results.126-128 
Whereas Canestaro et al. and Harrington et al. found that apixaban 5mg was a cost-effective 
strategy compared to dabigatran 150mg, Coyle and colleagues showed that dabigatran 150mg 
was more expensive and less effective than apixaban 5mg.126-128 Because edoxaban was recently 
approved, only three cost-effectiveness studies have included this agent among the strategies 
compared, all of which were based on European countries.130-132 In these studies, edoxaban  
60mg was found to be a cost-effective strategy compared to warfarin,132 however, it was not 
favored when compared to apixaban 5mg.131 The results of these studies are not generalizable to 
the US because the cost-effectiveness of NOACs is highly sensitive to pricing, and the prices of 
NOACs are considerably higher in the US than in Europe.128 In summary, there is conflicting 
evidence on the comparative cost-effectiveness of apixaban 5mg and dabigatran 150mg, and the 
cost-effectiveness of edoxaban 60mg has never been evaluated from the US perspective. 
To address this evidence gap, we adopted a US perspective in comparing the cost-
effectiveness of edoxaban 60mg, apixaban 5mg, dabigatran 150mg, dabigatran 110mg, 
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rivaroxaban 20mg and dose-adjusted warfarin in the prevention of stroke and systemic embolism 
in AF patients with high risk of bleeding, as defined by HAS-BLED score equal to or greater 
than 3.163  
4.3 METHODS 
4.3.1 Overview of the Model 
We constructed a Markov state-transition model to compare the cost-effectiveness of edoxaban 
60mg, apixaban 5mg, dabigatran 150mg, dabigatran 110mg, rivaroxaban 20mg and dose-
adjusted warfarin in the prevention of stroke and systemic embolism in AF patients at high risk 
of bleeding. The base case analysis included a cohort of 65-year old patients with AF, elevated 
risk of stroke (CHADS2 score≥1), high risk of bleeding (HAS-BLED≥3), normal kidney 
function (creatinine clearance≥50ml/min), no contraindications for oral anticoagulation use, and 
who did not use P-glycoprotein inhibitors or CYP3A4 inhibitors. Because edoxaban is only 
indicated in patients with creatinine clearance lower than 95ml/min, we re-run our analyses after 
including and excluding edoxaban from the compared strategies. 72The following states were 
simulated in the model: AF on an oral anticoagulant agent, AF on aspirin, severe stroke, other 
thromboembolic events including minor ischemic stroke, transient ischemic attack and systemic 
embolism, intracranial bleeding, extracranial bleeding and death (Figure 4-1). Transitions 
between health states were modeled using 1-year cycles, and patients were followed until death 
or until 90 years of age. Patients reaching the 35th cycle alive were assumed to die at the age of 
90. Future costs and benefits were discounted at a 3% annual rate. From the perspective of US-
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based third party payers, we quantified costs in 2012 US dollars, effectiveness in QALYs, and 
calculated incremental cost effectiveness ratios (ICERs). The model was constructed and 
analyzed using TreeAge Pro Suite 2015 (Williamstown, MA). 
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Figure 4-1: Markov Model 
4.3.2 Major Model Assumptions 
We made the following assumptions: First, patients entering the model are treated with aspirin 
and one of the following anticoagulant agents: edoxaban 60mg, apixaban 5mg, dabigatran 
150mg, dabigatran 110mg, rivaroxaban 20mg or dose-adjusted warfarin (target international 
normalized ratio [INR] between 2 and 3).60 Therapy adherence was assumed to be similar across 
all treatments.128 Second, during each Markov cycle, patients can experience a severe stroke, 
82 
other thromboembolic event including minor ischemic stroke, transient ischemic attack and 
systemic embolism, an intracranial bleeding or an extracranial bleeding event. After 
experiencing a severe stroke or other thromboembolic event, patients resume aspirin and 
anticoagulation with the same agent used before the thromboembolic event. However, we 
assumed that all patients discontinue anticoagulation therapy after experiencing an intracranial 
hemorrhage.164 Based on the FDA summary of the ROCKET-AF trial, 10% of the patients who 
experienced an extracranial bleeding were assumed to discontinue oral anticoagulation.165 
Patients who discontinue oral anticoagulation after an extracranial bleed proceed to the AF on 
aspirin state. Third, patients that experience a severe stroke or intracranial bleeding remain in 
states denoting those events permanently. Fourth, the efficacy and safety of all treatments were 
assumed to be constant over time. Fifth, patients who do not discontinue anticoagulation use the 
same anticoagulant agent throughout their lifetime.  
4.3.3 Input Parameters  
4.3.3.1 Clinical Probabilities 
The annual probabilities of severe stroke, other thromboembolic events, and intracranial bleeding 
with warfarin were obtained from the RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE AF-
TIMI trials (Table 4-1).88-91 The annual probability of extracranial bleeding represents the annual 
probability of extracranial bleeding in a cohort of AF patients on warfarin and with HAS-BLED 
between 3 and 5, weighted by the proportion of patients with HAS-BLED score 3, 4 and 5, 
respectively.166 The annual probability of other thromboembolic events was calculated as the 
sum of the probabilities of minor ischemic stroke, transient ischemic attack or systemic 
embolism. For all clinical outcomes, event rates for treatments other than warfarin were 
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estimated using risk ratios relative to warfarin, and were obtained from the RE-LY, ROCKET-
AF, ARISTOTLE, and ENGAGE AF-TIMI trials and previously published cost-effectiveness 
analyses.88,89,121,167 To adjust the risk of stroke by age, we increased the risk of severe stroke by a 
factor of 1.4 every ten years of life.168  
Baseline mortality estimates by age were derived from the US National Vital Statistics 
Reports.155 For patients who survive a major stroke, other thromboembolic event or an 
intracranial hemorrhage, we increased their mortality risk according to post-event mortality risks 
derived from previous publications, because they are more likely to die compared with those 
who did not experience such events.121,169,170 For instance, the baseline annual mortality rate for 
an average 75-year-old patient was 0.031, but the annual mortality rate for a 75-year-old patient 
with a history of severe stroke was estimated at 0.074 (0.031+0.043), because the increase in 
mortality rate associated with experiencing a severe stroke was 0.043.169  
4.3.3.2 Costs 
We obtained the cost for one-year supply of apixaban, edoxaban, dabigatran, rivaroxaban and 
warfarin from www.goodrx.com, and the cost of aspirin was based on a previous publication.171 
The total cost of warfarin treatment was calculated as the sum of one-year supply of warfarin and 
the annual costs for INR monitoring.172 Estimates for the one-time costs, or the costs of acute 
care provided for clinical events were obtained from the Healthcare and Utilization Project 
(HCUP).173 The maintenance costs associated with the follow-up care of patients who 
experienced clinical events were obtained from two retrospective analyses.174,175 For both one-
time and follow-up costs, the costs of other thromboembolic events were calculated as the 
average of the costs of minor ischemic stroke, transient ischemic attack and systemic embolism, 
weighted by their respective annual probability. Costs of healthcare related to diseases other than 
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AF, thromboembolic or bleeding events were obtained from the Medical Expenditure Panel 
Survey (MEPS) data.176 The ranges used for sensitivity analyses were calculated as ±20% of the 
base case. All costs except for drug costs were inflated to 2012 US dollars using the Consumer 
Price Index for medical care.177 Drug costs were not deflated to 2012 US dollars because some of 
the NOACs were not available in the market at that time (apixaban was approved in December 
2012 and edoxaban in January 2015). 
4.3.3.3 Quality-of-life Measures 
Utilities represent the preference for a health state and range from 0 to 1, with 0 denoting death 
and 1 perfect health. To adjust life expectancy for quality of life, we multiplied the time spent in 
each heath state and its respective utility. For example, if a patient spent two years on a state of 
utility 0.8, the total quality-adjusted life years accrued in such state would be 1.6 (2*0.8). The 
baseline utility in all cycles was adjusted for age, AF, and anticoagulation use.178-180 For 
example, the utility accrued when a 70-year old patient spent one year on the severe stroke state 
would equal 0.35 [(0.84(utility associated with 70 years of age)*0.989(utility associated with the 
use of anticoagulation)*0.81(utility associated with AF) *0.514(utility associated with severe 
stroke)]. The utility estimates for severe stroke, other thromboembolic events, intracranial 
bleeding and extracranial bleeding were obtained from a catalogue of EQ-5D scores by Sullivan 
et al. and other relevant publications.164,181-183 The utility estimate for other thromboembolic 
events was calculated as the average of the utilities of minor ischemic stroke, transient ischemic 
attack and systemic embolism, weighted by their respective annual probability. 
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Table 4-1: Decision Model Inputs: Event Probabilities, Mortality Estimates, Costs and Utilities 
Input Variable Base Case Range  References 
Clinical Parameters 
     Annual probability of severe stroke on warfarin  0.0040 0.0020-0.0063 88,89 
     Percentage of severe strokes that are fatal (%) 16.94 14.00-20.00 121 
     RR of severe stroke aspirin vs warfarin 2.16 1.57-2.82 121,167 
     RR of severe stroke dabigatran 150mg vs warfarin 0.76 0.60-0.98 88 
     RR of severe stroke dabigatran 110mg vs warfarin 1.11 0.89-1.40 88 
     RR of severe stroke rivaroxaban 20mg vs warfarin 0.89 0.65-1.21 167 
     RR of severe stroke apixaban 5mg vs warfarin 0.79 0.65-0.95 90 
     RR of severe stroke edoxaban 60mg vs warfarin 0.97 0.76-1.23 91 
  Annual probability of other thromboembolic event on warfarin  0.0146 0.0100-0.0200 88,89,167,184 
     RR of other thromboembolic event aspirin vs warfarin 1.82 1.12-3.02 88,184 
     RR of other thromboembolic event dabigatran 150mg vs warfarin 0.71 0.47-1.09 88,185 
     RR of other thromboembolic event dabigatran 110mg vs warfarin 0.68 0.46-1.01 88,185 
     RR of other thromboembolic event rivaroxaban 20 mg vs warfarin 0.79 0.66-0.96 89 
     RR of other thromboembolic event apixaban 5mg vs warfarin 0.80 0.64-1.03 90 
     RR of other thromboembolic event edoxaban 60mg vs warfarin 0.78 0.62-1.02 91 
  Annual probability of intracranial hemorrhage on warfarin 0.0080 0.0074-0.0094 88,89,128 
     Percentage of intracranial hemorrhages that are fatal (%) 42.00 35.00-60.00 122 
     RR of intracranial hemorrhage aspirin vs warfarin 0.51 0.16-1.60 184 
     RR of intracranial hemorrhage dabigatran 150mg vs warfarin 0.40 0.27-0.60 88 
     RR of intracranial hemorrhage dabigatran 110mg vs warfarin 0.31 0.20-0.47 88 
     RR of intracranial hemorrhage rivaroxaban 20mg vs warfarin 0.67 0.47-0.93 165 
     RR of intracranial hemorrhage apixaban 5mg vs warfarin 0.42 0.30-0.58 90 
     RR of intracranial hemorrhage edoxaban 60mg vs warfarin 0.47 0.34-0.63 91 
  Annual probability of extracranial hemorrhage on warfarin 0.0590 0.0410-0.0910 166 
     Percentage of extracranial hemorrhages that are fatal (%) 5.88 3.00-8.00 186 
     RR of extracranial hemorrhage aspirin vs warfarin 0.43 0.24-0.75 167 
     RR of extracranial hemorrhage dabigatran 150mg vs warfarin 1.07 0.92-1.25 88 
     RR of extracranial hemorrhage dabigatran 110mg vs warfarin 0.94 0.80-1.10 88 
     RR of extracranial hemorrhage rivaroxaban 20mg vs warfarin 1.15 0.91-1.41 167 
     RR of extracranial hemorrhage apixaban 5mg vs warfarin 0.79 0.68-0.93 90 
     RR of extracranial hemorrhage edoxaban 60mg vs warfarin 0.91 0.80-1.05 91 
  Mortality parameters 
        Increase in mortality after severe stroke 0.0427 0.0337-0.0537 169 
     Increase in mortality after other thromboembolic event 0.0100 0.0030-0.0170 121 
     Increase in mortality after intracranial hemorrhage 0.0660 0.0500-0.0800 170 
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Table 4-1 continued  
 
Costs (2012 US Dollars) 
  Annual treatment costs 
   Aspirin 13.95 11.16-16.74 171 
     Warfarin 162.41 129.93-194.89 171 
     Dabigatran 150mg 4915.15 3932.12-5898.18 187 
     Dabigatran 110mg 4915.15 3932.12-5898.18 187 
     Rivaroxaban 20mg 4092.48 3273.98-4910.98 187 
     Apixaban 5mg 4095.96 3276.77-4915.15 187 
     Edoxaban 60mg 3420.00 2736.00-4104.00 187 
  Annual cost of INR monitoring 1110.38 888.30-1332.46 172 
  One-time costs 
        Severe stroke  14843.00 11874.40-17811.60 173 
     Other thromboembolic event 7424.49 5939.60-8909.39 173 
     Intracranial hemorrhage   21256.00 17004.80-25507.20 173 
     Extracranial hemorrhage 7100.00 5680.00-8520.00 173 
  Long-term maintenance costs 
        Severe Stroke 30333.82 24267.06-36400.58 175 
     Other thromboembolic event 18735.00 14988.00-22482.00 174 
     Intracranial hemorrhage 23278.51 18622.81-27934.21 188 
     Other costs 9678.00 7742.40-11613.60 176 
Quality-of-life Estimates 
        Anticoagulation 0.989 0.0988-0.991 178 
     Atrial Fibrillation 0.810 0.700-0.900 180 
     Severe stroke 0.514 0.454-0.574 181 
     Other thromboembolic event 0.620 0.560-0.680 181 
     Intracranial hemorrhage  0.600 0.020-1.000 188 
     Extracranial hemorrhage 0.800 0.500-0.990 189 
4.3.4 Sensitivity Analysis 
We performed multiple sensitivity analyses of the input variables over the ranges shown in Table 
1. First, we conducted a series of one-way sensitivity analyses to evaluate the relative importance 
of each parameter, and we identified the threshold of variables at which the anticoagulant 
strategy favored changed. Second, we performed three-way sensitivity analyses to identify the 
preferred anticoagulant agent over the plausible ranges of annual probabilities of severe stroke 
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and of extracranial bleeding, for the base-case value of the annual probability of intracranial 
bleeding, as well as the upper and lower bound estimates. Third, we simultaneously varied all 
parameter values 10,000 times in a Monte Carlo probabilistic sensitivity analysis and constructed 
a cost-effectiveness acceptability curve. We modelled event probabilities and utilities as beta 
distributions, relative risk of events as log-normal distributions, and costs as gamma 
distributions. To select cost-effective alternatives, we used $100,000 per QALY gained as 
willingness-to-pay (WTP) threshold, because this is the most  realistic WTP criterion in the US 
context.190 
4.4 RESULTS 
4.4.1 Base-case Analysis 
Table 4-2 shows the costs and effectiveness associated with each treatment, as well as the 
incremental cost-effectiveness results. In the base case scenario, apixaban 5mg had the highest 
effectiveness (8.32 QALYs), followed by dabigatran 110mg (8.31), dabigatran 150mg (8.30), 
edoxaban 60mg (8.25), rivaroxaban 20mg (8.13), and warfarin (7.96). Dabigatran 110mg was the 
most expensive treatment ($223,922), followed by dabigatran 150mg ($220,927), apixaban 5mg 
($214,614), rivaroxaban 20mg ($212,579), edoxaban 60mg ($206,336) and warfarin ($184,525).  
When edoxaban was included in the analysis, treatment with edoxaban 60mg cost $77,565 
per QALY gained compared to warfarin, and the ICER of apixaban 5mg compared to edoxaban 
60mg was $108,631/QALY. When edoxaban was not included in the analysis, treatment with 
apixaban 5mg would cost $84,128 per QALY gained, compared to anticoagulation therapy with 
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warfarin. Regardless of the inclusion of edoxaban, rivaroxaban 20mg, dabigatran 150 mg and 
dabigatran 110mg were dominated strategies, because treatment with apixaban 5mg was more 
effective and less costly. If apixaban 5mg was also excluded from the analysis, rivaroxaban 
would be dominated by dabigatran, and the ICER of dabigatran 150mg compared to warfarin 
would be $107,080/QALY. 
 
Table 4-2: Base-case Analysis Results: Total and Incremental Costs and Quality-Adjusted Life Years per 
Patient. 
Including edoxaban 
in the analysis
Cost (2012 US 
Dollars)
Effectiveness 
(QALYs)
    Incremental Costs 
(2012 US Dollars)
    Incremental 
Effectiveness (QALYs)
    ICERs 
($/QALY)
Warfarin 184,252 7.9615 -- -- --
Edoxaban 60mg 206,336 8.2462 22,084 0.2847 77,565
Rivaroxaban 20mg 212,579 8.1349 6,243 -0.1113 Dominated
Apixaban 5mg 214,614 8.3224 8,278 0.0762 108,631
Dabigatran 150mg 220,927 8.304 6,313 -0.0184 Dominated
Dabigatran 110mg 223,922 8.3058 9,309 -0.0166 Dominated
Excluding edoxaban 
from the analysis
Cost (2012 US 
Dollars)
Effectiveness 
(QALYs)
    Incremental Costs 
(2012 US Dollars)
    Incremental 
Effectiveness (QALYs)
    ICERs 
($/QALY)
Warfarin 184,252 7.9615 -- -- --
Rivaroxaban 20mg 212,579 8.1349 28,327 0.1734 Dominated
Apixaban 5mg 214,614 8.3224 2,035 0.1875 84,129
Dabigatran 150mg 220,927 8.3040 6,313 -0.0184 Dominated
Dabigatran 110mg 223,922 8.3058 9,309 -0.0166 Dominated  
 
Table 4-3 shows the clinical events experienced per 1000 AF patients entering the model 
and receiving each of the six oral anticoagulation agents. Compared to warfarin, edoxaban 60mg 
would prevent 37 thromboembolic events other than severe strokes, 57 intracranial hemorrhages 
and 27 extracranial bleeding events; however, warfarin would prevent 2 severe strokes more than 
edoxaban 60mg. Compared to warfarin, apixaban 5mg would prevent 12 severe strokes, 190 
other thromboembolic events, 45 intracranial hemorrhages and 112 extracranial bleeding events. 
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Use of apixaban 5mg as compared to edoxaban 60mg would prevent 14 severe strokes, 4 
intracranial hemorrhages, and 85 extracranial bleeding events, but edoxaban 60mg would 
prevent 7 other thromboembolic events more than apixaban 5mg.  
 
Table 4-3: Base-case Analysis Results: Clinical Events per Cohort of 1000 Patients. 
 
Number of lifetime events per 
cohort of 1000  Warfarin 
Rivaroxaban 
20mg 
Edoxaban 
60mg 
Dabigatran 
150mg 
Dabigatran 
110mg 
Apixaban 
5mg 
   Severe Stroke 84 78 86 70 98 72 
   Other Thromboembolic Events 220 182 183 170 161 190 
   Intracranial Hemorrhage 114 79 57 50 39 53 
   Extracranial Hemorrhage 829 971 802 941 833 717 
  
4.4.2 Sensitivity Analysis 
In one-way sensitivity analyses, we identified variables that most influenced the strategy favored 
at the $100,000 per QALY gained threshold (Table 4-4). The optimal anticoagulation choice was 
most sensitive to the annual probability of extracranial bleeding and of thromboembolic events 
other than severe stroke, the proportion of extracranial hemorrhages that are fatal, the relative 
risk of clinical events with apixaban 5mg, edoxaban 60mg and dabigatran 150mg compared to 
warfarin, the costs of apixaban 5mg, edoxaban 60mg, and dabigatran, and the quality of life 
associated with AF and with an extracranial bleeding. When the annual cost of apixaban 5mg 
was below $4,044 (98.7% of the base-case value), apixaban 5mg was the preferred strategy at the 
$100,000 per QALY WTP threshold. Apixaban 5mg was also preferred when the annual 
probability of extracranial bleeding was higher than 8%. We found that under no scenario, 
warfarin or rivaroxaban 20mg were the preferred strategies at the $100,000 per QALY WTP 
threshold. When edoxaban was excluded from the analysis, the optimal anticoagulation choice at 
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the $100,000 per QALY gained threshold was only sensitive to the annual cost of dabigatran 
110mg and 150mg, and the relative risk of other thromboembolic events with dabigatran 150mg, 
compared to warfarin. 
 
Table 4-4: One Way-Sensitivity Analysis: Influential Parameters and Their Thresholds for the Choice of 
Favored Strategy at $100,000/Quality-Adjusted Life Year Willingness to Pay 
Parameter Base-case value Threshold
Strategy favored 
below threshold
Strategy favored 
above threshold 
Annual risk of Extracranial Bleeding 0.059 0.080 Edoxaban 60mg Apixaban 5mg
Annual risk of Other Thromboembolic Events 0.0146 0.012 Apixaban 5mg Edoxaban 60mg
Proportion of Fatal Extracranial Hemorrhages 5.88 7.95 Edoxaban 60mg Apixaban 5mg
Relative Risk Severe Stroke
    Apixaban 5mg vs Warfarin 0.79 0.77 Apixaban 5mg Edoxaban 60mg
    Edoxaban 60mg vs Warfarin 0.97 0.99 Edoxaban 60mg Apixaban 5mg
Relative Risk Other Thromboembolic Events
    Apixaban 5mg vs Warfarin 0.8 0.79 Apixaban 5mg Edoxaban 60mg
     Dabigatran 150mg vs Warfarin 0.71 0.53 Dabigatran 150mg Edoxaban 60mg
     Edoxaban 60mg vs Warfarin 0.78 0.79 Edoxaban 60mg Apixaban 5mg
Relative Risk Intracranial Hemorrhage
    Apixaban 5mg vs Warfarin 0.42 0.40 Apixaban 5mg Edoxaban 60mg
    Edoxaban 60mg vs Warfarin 0.47 0.49 Edoxaban 60mg Apixaban 5mg
Relative Risk Extracranial Hemorrhage
    Apixaban 5mg vs Warfarin 0.79 0.74 Apixaban 5mg Edoxaban 60mg
    Edoxaban 60mg vs Warfarin 0.91 0.96 Edoxaban 60mg Apixaban 5mg
Cost of Apixaban 5mg 4,096 4,044 Apixaban 5mg Edoxaban 60mg
Cost of Dabigatran 110mg 4,915 3,986 Dabigatran 110mg Edoxaban 60mg
Cost of Dabigatran 150mg 4,915 4,205 Dabigatran 150mg Edoxaban 60mg
Cost of Edoxaban 60mg 3,420 3,473 Edoxaban 60mg Apixaban 5mg
Quality of Life Extracranial Bleeding 0.80 0.64 Apixaban 5mg Edoxaban 60mg
Quality of Life Non-Valvular Atrial Fibrillation 0.81 0.88 Edoxaban 60mg Apixaban 5mg
Parameter Base-case value Threshold
Strategy favored 
below threshold
Strategy favored 
above threshold 
Relative Risk Other Thromboembolic Events
     Dabigatran 150mg vs Warfarin 0.71 0.54 Dabigatran 150mg Apixaban 5mg
Cost of Dabigatran 110mg 4,915 4,038 Dabigatran 110mg Apixaban 5mg
Cost of Dabigatran 150mg 4,915 4,258 Dabigatran 150mg Apixaban 5mg
Including edoxaban in the analysis
Excluding edoxaban from the analysis
 
The results of the three-way sensitivity analyses are shown in Figure 4-2. We found that, 
regardless of the risk of extracranial bleeding and the risk of intracranial bleeding, edoxaban 60 
mg was the strategy preferred when the annual probability of severe stroke at baseline was lower 
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than 0.42 (the base-case for the annual probability of severe stroke was 0.40). When the annual 
probability of severe stroke was higher than 0.42, the preferred strategy depended on the 
probabilities of intracranial and extracranial bleeding. Under no circumstances were rivaroxaban 
20mg, dabigatran 150mg, dabigatran 110mg or warfarin the preferred strategies. When edoxaban 
was excluded from the analysis, apixaban 5 mg was the preferred strategy for all ranges of 
annual probabilities of severe stroke, intracranial and extracranial bleeding events.  
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Figure 4-2: Three-Way Sensitivity Analysis. 
A) Results when edoxaban was included in the analysis. 
B) Results when edoxaban was excluded from the analysis. 
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Our base-case scenario results are consistent with the findings from probabilistic sensitivity 
analyses (Figure 4-3). Varying all input parameters simultaneously in a Monte Carlo simulation, 
we found that at the $100,000 per QALY WTP threshold, edoxaban 60mg had the highest 
likelihood to be the most cost-effective strategy (40%), followed by apixaban 5mg (36%), 
dabigatran 150mg (11%) dabigatran 110mg (8%), warfarin (5%) and rivaroxaban 20 mg (1%). 
Apixaban 5mg had the highest likelihood to be the most cost-effective alternative for WTP 
thresholds above $115,000/QALY.  For WTP thresholds lower than $75,000/QALY, warfarin 
was likely to be the more cost-effective option. For any WTP threshold, the probability of 
rivaroxaban 20mg to be the most cost effective strategy was lower than 2%. When edoxaban was 
excluded from the analysis, apixaban 5mg was likely to be the more cost-effective option for 
WTP thresholds above $80,000/QALY. 
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Figure 4-3: Cost-Effectiveness Acceptability Curve. 
A) Results when edoxaban was included in the analysis 
B) Results when edoxaban was excluded from the analysis. 
95 
4.5 DISCUSSION 
To the best of our knowledge, our study is the first one to compare the cost-effectiveness of all 
NOACs approved up to this date in a simulated population of AF patients at high risk of bleeding 
from the US perspective. Our study has three main findings. First, for patients with creatinine 
clearance between 50 and 95 ml/min, edoxaban 60 mg was the most cost-effective treatment at 
the $100,000 per QALY WTP threshold; however, the ICER of apixaban 5mg compared to 
edoxaban 60mg was slightly above this threshold. The cost-effectiveness of apixaban 5mg and 
edoxaban 60mg was mostly influenced by the annual probability of extracranial bleeding and of 
thromboembolic events, the risk of clinical events with apixaban 5mg and edoxaban 60mg, and 
the costs of apixaban 5mg and edoxaban 60mg. For this population, apixaban 5mg would be a 
cost-effective strategy if its price was reduced by 1.3%, while the price of edoxaban 60mg was 
maintained constant, or  if a more liberal criterion of WTP was used.191 Second, for patients with 
creatinine clearance higher than 95ml/min, for whom edoxaban 60mg is not indicated, apixaban 
5mg was the most cost-effective treatment at the $100,000 per QALY WTP threshold.  Third, 
regardless of the levels of creatinine clearance, rivaroxaban 20mg, dabigatran 150 mg and 
dabigatran 110mg were dominated strategies, because treatment with apixaban 5mg was more 
effective and less costly.  
When we directly compared the cost-effectiveness of apixaban and warfarin, we found that 
treatment with apixaban cost $84,128 per QALY gained, compared to warfarin; which is 
consistent with the ICER reported by Canestaro et al. in a recent study ($93,063/QALY).126 In 
addition, our estimate for the ICER of edoxaban compared to warfarin ($77,565/QALY) is 
similar to the Germany-based estimate by Krejczy et al. (€52,000 or $57,000);130 however, it is 
considerably higher than the ICER estimated by Rognoni et al. from the perspective of the Italian 
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National Health System (€7,713 or $8,422).132 The substantially higher prices of on-patent drugs 
in the US and Germany as compared to Italy may explain why the ICER of apixaban versus 
warfarin estimated by Rognoni et al. is considerably lower than our result and the estimate by 
Krejczy and collaborators.192 To the best of our knowledge, only one study has directly 
compared the cost-effectiveness of apixaban 5mg and edoxaban 60mg. In this study, Lip et al. 
adopted a UK National Health System (NHS) perspective, and estimated the ICER of apixaban 
5mg compared to edoxaban 60mg at £6,763 or $9,993 per QALY gained.131 The difference 
between this result and our estimate ($108,631/QALY) can be explained by the comparative 
pricing of edoxaban and apixaban in the UK and the US: In the UK, the cost of apixaban (£804 
or $1,187) is identical to that of edoxaban UK (£804 or $1,187), whereas the cost of apixaban in 
the US ($4,096) is 20% higher than that of edoxaban ($3,420).131   
Our study is subject to three main limitations. First, we assumed that treatment adherence 
and discontinuation rates were similar across treatments. This may not be true for two reasons: 
First, the copayment faced by Medicare Part D beneficiaries towards new oral anticoagulants is 
considerably higher than the copayment for warfarin. Second, treatment with new oral 
anticoagulants does not require INR monitoring, whereas warfarin does. Nevertheless, potential 
differences in the adherence and discontinuation rates between treatments are not likely to affect 
the ICER of apixaban 5mg compared to edoxaban 60mg, one of the main findings of our study. 
Second, we assumed that the risk of bleeding with all anticoagulant agents was constant over 
time. It remains unknown how the risk of bleeding with new oral anticoagulant changes over 
time; however, the risk of bleeding on warfarin has been shown to decrease 90 days after 
treatment initiation.138 Nevertheless, we modeled transitions between health states using 1-year 
cycles, so this should not affect our results. Third, because patients in clinical trials are closely 
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monitored, time in the target INR range with warfarin may be higher for patients in clinical trials 
than in the real-word clinical setting. Therefore, the probabilities of clinical events and the risk 
ratios of events for new oral anticoagulants compared to warfarin may under-estimate the risk of 
these events in the real-world setting. However, this should not affect our direct comparisons of 
NOACs. 
Despite these limitations, our study has important implications for the management of 
anticoagulation in AF patients with high risk of bleeding. In clinical trials, apixaban 5mg was the 
only new oral anticoagulant agent to show superiority in both efficacy and safety compared to 
warfarin, and to show a benefit in terms of survival.82,90 In the current study, we found that, 
among all oral anticoagulation agents currently available, apixaban is the most effective strategy 
in the prevention of stroke and systemic embolism among AF patients at high risk of bleeding. 
For patients with creatinine clearance equal to or lower than 95ml/min, for whom edoxaban 
60mg is indicated,  apixaban would be cost-effective at the $100,000 per QALY WTP threshold 
if its price was reduced by 1.3%, while the price of edoxaban was maintained constant. On the 
other hand, if a more liberal willingness-to-pay criterion was used, for instance, $150,000 or 
more per QALY gained,191 apixaban would also be the favored anticoagulation strategy for this 
population. Because in the US there is no WTP criterion explicitly used, the optimal choice 
between edoxaban and apixaban will likely depend on the willingness-to-pay of third party 
payers, as well as on the rebates that health plans negotiate with pharmaceutical manufacturers. 
For patients with creatinine clearance higher than 95ml/min, for whom edoxaban 60mg is not 
indicated, apixaban 5mg is likely to be the most cost-effective strategy. In addition, our study 
found that, in the base case scenario, dabigatran and rivaroxaban were dominated strategies. 
These findings suggest that, in the formulary making process, health plans should categorize 
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apixaban or edoxaban as preferred brand names, whereas the dominated NOACs dabigatran and 
rivaroxaban should be placed in higher tiers. Such categorization of NOACs would incentivize 
the use of agents whose cost-effectiveness is supported by evidence.  
In conclusion, we found that under current pricing, edoxaban 60mg was the most cost-
effective oral anticoagulation treatment in the prevention of stroke and systemic embolism in AF 
patients with high risk of bleeding and creatinine clearance equal to or lower than 95ml/min. 
Apixaban 5mg, however, was the most effective strategy and it would be cost-effective for this 
population if its price was reduced 1.3%, or if a somewhat higher cost-effectiveness criterion of 
$150,000/QALY gained or more was used. For patients with creatinine clearance higher than 
95ml/min, for whom edoxaban is not indicated, apixaban 5mg was the most cost-effective oral 
anticoagulation treatment. 
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5.0  SYNTHESIS 
5.1 OVERVIEW OF RESEARCH FINDINGS 
This dissertation evaluated several aspects of the safety, effectiveness and cost-effectiveness of 
non-vitamin K antagonist oral anticoagulants in the prevention of stroke and systemic embolism 
among Medicare beneficiaries with atrial fibrillation patients.  Our research yielded the 
following findings: 
5.1.1 Comparative Effectiveness and Safety of Rivaroxaban and Dabigatran 
When comparing the effectiveness and safety of two doses of dabigatran and two doses of 
rivaroxaban in a cohort of Medicare beneficiaries with AF, we found no differences in the risk of 
stroke between dabigatran 150mg and rivaroxaban 20mg (HR 1.05, 95%CI 0.97-1.13) or 
between dabigatran 75mg and rivaroxaban 15mg (HR1.05, 95%CI 0.94-1.18). Compared to 
dabigatran 150mg, rivaroxaban 20mg was associated with higher risk of other thromboembolic 
events (HR1.28, 95%CI 1.14-1.44), major bleeding (HR1.32, 95%CI 1.17-1.50), and death 
(HR1.36, 95% CI 1.19-1.56). The risk of thromboembolic events other than stroke (HR1.37, 
95%CI 1.15-1.62), major bleeding (HR1.51, 95%CI 1.25-1.82) and death (HR1.21, 95% CI 1.04-
1.41) was also higher for rivaroxaban 15mg than dabigatran 75mg. Our results for the 
comparative risk of stroke, death, major bleeding and intracranial bleeding in three high risk 
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subgroups (patients older than 75 years, with kidney disease or with 7 CMS priority conditions 
other than AF) were consistent with the findings from the overall sample. 
5.1.2 Post-hemorrhage Use of Anticoagulation and Clinical Outcomes 
We identified a cohort of AF patients who had a major bleeding event that required 
hospitalization while using warfarin and dabigatran, and categorized them according to their 
post-hemorrhage anticoagulation use. We observed that over half of the patients who had a 
bleeding event on warfarin or dabigatran did not resume anticoagulation therapy. The post-
hemorrhage use of warfarin was considerably more common than the use of dabigatran: Only 
28% of patients who bled on dabigatran resumed this NOAC after the bleeding event, whereas 
41% of warfarin users resumed warfarin (p-value<0.001). In addition, 17% of dabigatran users 
switched to warfarin after the bleeding event, compared to 2% of warfarin users that switched to 
dabigatran (p-value<0.001).  
We studied which factors affect the resumption of anticoagulation after a major bleeding 
event, and found that CHA2DS2-VAsc and HAS-BLED scores did not impact the likelihood of 
anticoagulation resumption. The odds of resuming anticoagulation decreased however by 11% 
(95%CI, 4%-18%) and 24% (95%CI, 9%-37%) for every 5 years increase in age for warfarin and 
dabigatran users, respectively. In addition, warfarin users who experienced intracranial bleeding, 
were admitted to the intensive care unit, or received a blood transfusion were more likely to 
discontinue anticoagulation than those who did not. 
When comparing the clinical outcomes associated with the resumption of warfarin or 
dabigatran and the discontinuation of anticoagulation after a major bleeding event, we found that 
post-hemorrhage resumption of anticoagulation with warfarin (HR0.76; 95%CI, 0.59-0.97) or 
101 
dabigatran (HR0.66; 95%CI 0.44-0.99) was associated with lower combined risk of ischemic 
stroke and all-cause mortality than anticoagulation discontinuation. Furthermore, resumption of 
warfarin (HR0.35; 95%CI, 0.23-0.53) or dabigatran (HR0.13; 95%CI, 0.04-0.41) was associated 
with decreased mortality, compared to anticoagulation discontinuation. The incidence of 
recurrent major bleeding was higher for patients who were prescribed warfarin after the bleeding 
event than for those prescribed dabigatran (HR2.31; 95%CI, 1.19-4.76) or whose anticoagulation 
ceased (HR1.56; 95%CI, 1.10-2.22). 
5.1.3 Comparative Cost-Effectiveness of NOACs 
We compared the cost-effectiveness of edoxaban 60mg, apixaban 5mg, dabigatran 150mg, 
dabigatran 110mg, rivaroxaban 20mg and dose-adjusted warfarin in the prevention of stroke and 
systemic embolism among 65 year old AF patients with HAS-BLED scores equal to or greater 
than 3. We found that in the base case scenario, apixaban 5mg had the highest effectiveness, 
followed by dabigatran 110mg, dabigatran 150mg , edoxaban 60mg, rivaroxaban 20mg, and 
warfarin. Dabigatran 110mg was the most expensive treatment, followed by dabigatran 150mg, 
apixaban 5mg, rivaroxaban 20mg, edoxaban 60mg and warfarin.  Rivaroxaban 20mg, dabigatran 
150 mg and dabigatran 110mg were dominated strategies, because treatment with apixaban 5mg 
was more effective and less costly. After excluding these three dominated strategies, we found 
that treatment with edoxaban 60mg cost $77,565 per QALY gained compared to warfarin, and 
the ICER of apixaban 5mg compared to edoxaban 60mg was $108,631/QALY. Because 
edoxaban is only indicated in patients with creatinine clearance ≤95ml/min, we re-run our 
analyses after excluding edoxaban from the compared strategies, finding that the ICER of 
apixaban 5mg compared to warfarin was $84,128 per QALY gained. 
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5.2 PUBLIC HEALTH SIGNIFICANCE 
The research presented in this dissertation has relevant implications for public health. The second 
leading cause of mortality in the world, stroke is responsible for around 10% of deaths 
worldwide.26 In addition, stroke is the third most common cause of disability in high-income 
countries.26 The most important single cause of ischemic stroke,23 AF is responsible for around 
15% of strokes in all age groups, and 24% in patients older than 80 years.24,25 The use of 
anticoagulation has consistently been associated with a 60% reduction in the risk of stroke in 
AF,40-45 yet, only around half of the AF patients whose use of anticoagulation is recommended 
by clinical guidelines actually receive anticoagulation therapy.193,194 Furthermore, a recent US 
based study found that the proportion of AF patients on anticoagulation did not increase with the 
risk of stroke, and did not exceed 50% even in patients with CHA2DS2-Vasc scores greater than 
4.195 The reasons behind the lack of concordance between clinical guidelines and real-life 
prescription of oral anticoagulants remain unknown; however, the reluctance to prescribe 
anticoagulation for patients at higher risk of stroke has been attributed to bleeding concerns,195 
since patients at highest risk of stroke are also at highest risk of bleeding.58,59,63,113 The balance of 
the risk of stroke and risk of bleeding, or in pharmacotherapy terms, the benefit/risk ratio of oral 
anticoagulant agents is crucial to the management of anticoagulation therapy among all AF 
patients, but it is especially relevant from the clinical perspective for this subgroup of AF 
patients at high risk of stroke and high risk of bleeding.  
Our research focused precisely on the use of anticoagulation by high-risk patients, and 
specifically, evaluated several aspects of the safety and effectiveness of NOACs and warfarin in 
the prevention of stroke in AF. Our research yielded relevant findings on the benefit risk/ratio of 
oral anticoagulants, which will impact the use and management of anticoagulation therapy in the 
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following ways: First, our results will orient clinicians in the prescription of the most appropriate 
NOAC according to the clinical characteristics of AF patients. Second, our findings will 
encourage the resumption of anticoagulation after a major bleeding event, which has been 
associated with increased survival and stroke-free survival. Specifically, our findings will 
incentivize the post-hemorrhage resumption of dabigatran, because with similar effectiveness 
than warfarin in the prevention of thromboembolic events, it was associated with lower risk of 
recurrent bleeding. Third, our research results will support the use of cost-effective anticoagulant 
strategies, incentivizing an optimal allocation of economic resources in healthcare. Fourth, our 
research will bring attention to the risk-aversion observed in the prescription patterns of NOACs, 
which prevents the use of the most effective anticoagulation strategy in each type of patient. The 
evidence arising from this dissertation on the benefit/risk ratio of different oral anticoagulation 
therapies will allow clinicians to become more familiar with the risks and benefits associated 
with each of the oral anticoagulation therapies currently available. This information will 
contribute to mitigate the risk-averse prescription patterns that prevent high-risk patients for 
whom anticoagulation is recommended from receiving anticoagulation therapy.195  
In summary, the evidence from this dissertation will guide clinicians in the prescription of 
the most effective, safe, and cost-effective anticoagulation agent according to the clinical 
characteristics of AF patients, and will contribute to close the gap between the clinical 
recommendations and the current use of anticoagulation. This will ultimately lead to the 
prevention of strokes, the second leading cause of mortality worldwide, and bleeding events, the 
most common complication of anticoagulation therapy.  
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5.3 DIRECTIONS FOR FUTURE RESEARCH 
Our research identified several gaps of evidence where further research will be needed in the 
future. First, as clinicians become more familiar with the use of NOACs, and as specific 
antidotes become available to reverse their anticoagulation effects in case of emergency, 
prescription patterns of NOACs will likely change. As a result, it will be necessary to compare 
the effectiveness and safety of NOACs as newer data becomes available. Second, our results for 
the comparative effectiveness and safety of oral anticoagulants will need to be validated in 
populations of AF patients other than Medicare beneficiaries. Third, it will be informative to 
conduct head-to-head analysis of all four NOACs and warfarin in the same population. This will 
be feasible in 2018, when Medicare Part D data that represents the period after the approval of 
edoxaban becomes available. Fourth, it will also be important to perform further subgroup 
analyses in the future for subgroups of AF patients other than the ones specifically evaluated in 
this dissertation. Fifth, clinical outcomes following a major bleeding event will likely depend on 
the anatomical location of the index hemorrhage. In future research, it will be informative to 
perform stratified analysis comparing the effectiveness and safety of anticoagulant resumption 
with each of the NOACs and warfarin, by anatomical location of the index bleeding event. Sixth, 
because results from cost-effectiveness analyses for NOACs are highly sensitive to their pricing, 
it will also be relevant to repeat similar pharmacoeconomic evaluations of NOACS as their 
prices change in the next few years.128   
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APPENDIX: SUPPLEMENTAL METHODS 
Frequency Matching 
To select a day to start following patients who interrupted anticoagulation after the index major 
hemorrhage, we performed frequency matching. To do so, we simulated the distribution of the 
time to restart of anticoagulation for the groups that filled a prescription for an oral 
anticoagulation agent after the index major hemorrhage. The time to restart of drug in the 
dabigatran cohort followed a gamma distribution with α=1.17 and σ=47.5. The time to restart of 
drug in the warfarin cohort followed a gamma distribution with α=1.12 and σ=54.2. Start date 
after index major hemorrhage was set up so that the window between the date of the index major 
hemorrhage and start date followed a similar distribution to that of the time to anticoagulation 
restart among the subjects that restarted anticoagulation after the index major bleeding event.  
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